<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">6HLCkKDcXFTBgf7Yvcp7JZn</article-id>
      <article-id pub-id-type="other">00006</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000900006</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300306</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000900006</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Import&#226;ncia da HDL-c para a ocorr&#234;ncia de doen&#231;a cardiovascular no idoso</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Freitas</surname>
            <given-names>Elizabete Viana de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brand&#227;o</surname>
            <given-names>Andr&#233;a Ara&#250;jo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pozzan</surname>
            <given-names>Roberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magalh&#227;es</surname>
            <given-names>Maria Eliane</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fonseca</surname>
            <given-names>Fl&#225;via</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pizzi</surname>
            <given-names>Oswaldo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campana</surname>
            <given-names>&#201;rika</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brand&#227;o</surname>
            <given-names>Ayrton Pires</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade do Estado do Rio de Janeiro</institution>
        <institution content-type="orgdiv1">Hospital Universit&#225;rio Pedro Ernesto </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>09</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>3</issue>
      <fpage>231</fpage>
      <lpage>238</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>09</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>21</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>11</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: Estudos sobre o impacto da HDL-c e ocorr&#234;ncia de doen&#231;a cardiovascular (CV) em idosos s&#227;o escassos. OBJETIVO: Avaliar as vari&#225;veis cl&#237;nicas e laboratoriais e a ocorr&#234;ncia de eventos CV em idosos estratificados de acordo com o comportamento da HDL-c em seguimento de oito anos. M&#201;TODOS: Foram avaliados, em dois momentos (A1 e A2), com espa&#231;o m&#237;nimo de cinco anos, 81 idosos, com idade m&#233;dia de 68,51 &#177; 6,32 (38,2% do sexo masculino). Os indiv&#237;duos foram divididos em 3 grupos de acordo com o n&#237;vel da HDL-c: HDL-c normal nas duas avalia&#231;&#245;es (GN) (n=31); HDL-c baixa nas duas avalia&#231;&#245;es (GB) (n=21); e HDL-c vari&#225;vel de A1 para A2 (GV) (n=29). Foram registrados os eventos CV maiores: doen&#231;a coronariana (angina, infarto mioc&#225;rdio, revasculariza&#231;&#227;o mioc&#225;rdica percut&#226;nea/cir&#250;rgica), acidente vascular encef&#225;lico, acidente isqu&#234;mico transit&#243;rio, doen&#231;a carot&#237;dea, dem&#234;ncia e insufici&#234;ncia card&#237;aca. RESULTADOS: Os grupos n&#227;o diferiram quanto &#224; idade e sexo em A1 e A2. As m&#233;dias dos triglic&#233;rides foram menores no GN em A1 (p=0,027) e A2 (p=0,016) que no GB. J&#225; a distribui&#231;&#227;o de eventos CV foi de 13 eventos no GN (41,9%), 16 (76,2%) no GB e de 12 (41,4%) no GV (&#967;2=7,149, p=0,024). Em an&#225;lise de regress&#227;o log&#237;stica observou-se que quanto maior a idade (OR=1,187, p=0,0230) e quanto menor a HDL-c (OR=0,9372, p=0,0102), maior a ocorr&#234;ncia de eventos CV. CONCLUS&#195;O: O HDL-c permanentemente baixo ao longo de oito anos de acompanhamento foi fator de risco para desenvolvimento de eventos CV em idosos.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Colesterol HDL</kwd>
        <kwd>sa&#250;de do idoso</kwd>
        <kwd>doen&#231;as cardiovasculares</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>22</day>
        <month>10</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> CARDIOGERIATRIA</p>
    <p>Import&#226;ncia da HDL-c para a ocorr&#234;ncia de doen&#231;a cardiovascular no idoso</p>
    <p>
      <bold>Elizabete Viana de Freitas; Andr&#233;a Ara&#250;jo Brand&#227;o; Roberto Pozzan; Maria Eliane Magalh&#227;es; Fl&#225;via Fonseca; Oswaldo Pizzi; &#201;rika Campana; Ayrton Pires Brand&#227;o</bold>
    </p>
    <p>Hospital Universit&#225;rio Pedro Ernesto, UERJ, Rio de Janeiro, RJ, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> Estudos sobre o impacto da HDL-c e ocorr&#234;ncia de doen&#231;a cardiovascular (CV) em idosos s&#227;o escassos. </p>
    <p><bold>OBJETIVO:</bold> Avaliar as vari&#225;veis cl&#237;nicas e laboratoriais e a ocorr&#234;ncia de eventos CV em idosos estratificados de acordo com o comportamento da HDL-c em seguimento de oito anos. </p>
    <p><bold>M&#201;TODOS:</bold> Foram avaliados, em dois momentos (A1 e A2), com espa&#231;o m&#237;nimo de cinco anos, 81 idosos, com idade m&#233;dia de 68,51 &#177; 6,32 (38,2% do sexo masculino). Os indiv&#237;duos foram divididos em 3 grupos de acordo com o n&#237;vel da HDL-c: HDL-c normal nas duas avalia&#231;&#245;es (GN) (n=31); HDL-c baixa nas duas avalia&#231;&#245;es (GB) (n=21); e HDL-c vari&#225;vel de A1 para A2 (GV) (n=29). Foram registrados os eventos CV maiores: doen&#231;a coronariana (angina, infarto mioc&#225;rdio, revasculariza&#231;&#227;o mioc&#225;rdica percut&#226;nea/cir&#250;rgica), acidente vascular encef&#225;lico, acidente isqu&#234;mico transit&#243;rio, doen&#231;a carot&#237;dea, dem&#234;ncia e insufici&#234;ncia card&#237;aca. </p>
    <p><bold>RESULTADOS:</bold> Os grupos n&#227;o diferiram quanto &#224; idade e sexo em A1 e A2. As m&#233;dias dos triglic&#233;rides foram menores no GN em A1 (p=0,027) e A2 (p=0,016) que no GB. J&#225; a distribui&#231;&#227;o de eventos CV foi de 13 eventos no GN (41,9%), 16 (76,2%) no GB e de 12 (41,4%) no GV (&#967;<sup>2</sup>=7,149, p=0,024). Em an&#225;lise de regress&#227;o log&#237;stica observou-se que quanto maior a idade (OR=1,187, p=0,0230) e quanto menor a HDL-c (OR=0,9372, p=0,0102), maior a ocorr&#234;ncia de eventos CV. </p>
    <p><bold>CONCLUS&#195;O:</bold> O HDL-c permanentemente baixo ao longo de oito anos de acompanhamento foi fator de risco para desenvolvimento de eventos CV em idosos. </p>
    <p><bold>Palavras-chave:</bold> Colesterol HDL / sa&#250;de do idoso, doen&#231;as cardiovasculares.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Em todo o mundo, o contingente de pessoas com idade igual ou superior a 60 anos tem crescido rapidamente<sup>1</sup>. O Brasil apresenta 10,5 % da sua popula&#231;&#227;o total de pessoas com idade igual ou superior a 60 anos, de acordo com os dados atualmente dispon&#237;veis no portal do IBGE, com uma expectativa de vida ao nascer atingindo em m&#233;dia 72,05 anos<sup>2</sup>. Por outro lado, a expectativa de vida dos que atingem os 60 anos vem crescendo de forma expressiva, modificando o perfil epidemiol&#243;gico, com grande preval&#234;ncia das doen&#231;as cardiovasculares nessa popula&#231;&#227;o<sup>3</sup>. </p>
    <p>Os dados epidemiol&#243;gicos mostram que a mortalidade por doen&#231;as cardiovasculares (DCV) aumenta com a idade. Esses n&#250;meros expressam a import&#226;ncia do processo da aterosclerose no idoso, tornando fundamental a sua preven&#231;&#227;o e detec&#231;&#227;o. Entretanto, estudos ainda incipientes no campo da geriatria mostram-se controversos quanto ao valor preditivo dos fatores de risco (FR) para DCV no idoso, principalmente ap&#243;s os 75 anos. </p>
    <p>Nas &#250;ltimas quatro d&#233;cadas, principalmente, os FR para as DCV v&#234;m sendo exaustivamente estudados<sup>4-7</sup>. O envelhecimento, a hipertens&#227;o arterial (HA), a dislipidemia, o diabete melito II (DM II), o fumo, o sedentarismo e a obesidade, por exemplo, est&#227;o entre os FR capazes de levar &#224; disfun&#231;&#227;o endotelial e, consequentemente, &#224; altera&#231;&#245;es vasculares com clara associa&#231;&#227;o entre esses fatores de risco e a aterosclerose<sup>6</sup>. </p>
    <p>A presen&#231;a de les&#245;es ateroscler&#243;ticas est&#225; associada, entre outros FR, com LDL colesterol (LDL-c) <underline>&gt;</underline> 100 mg/dl (2,6 mmol/L) e HDL colesterol (HDL-c) &lt; 40 mg/dl (1,04 mmol/L)<sup>8,9</sup>, enquanto, por outro lado, a HDL-c em n&#237;vel elevado tem sido reconhecida como antiaterog&#234;nica. Esse papel da HDL-c, apesar de ainda n&#227;o estar totalmente estabelecido, &#233; atribu&#237;do a sua capacidade de media&#231;&#227;o do transporte reverso do colesterol. </p>
    <p>Outros mecanismos protetores da HDL-c t&#234;m sido propostos, como a inibi&#231;&#227;o da oxida&#231;&#227;o da LDL-c, redu&#231;&#227;o da viscosidade sangu&#237;nea, regula&#231;&#227;o da s&#237;ntese de prostaglandinas e tromboxano e ativa&#231;&#227;o da fibrin&#243;lise, a&#231;&#227;o sobre a fun&#231;&#227;o endotelial e a&#231;&#227;o anti-inflamat&#243;ria<sup>10-12</sup>.</p>
    <p>No estudo EPESE<sup>13</sup>, foi sugerido que na popula&#231;&#227;o idosa o n&#237;vel de HDL-c &#233; um preditor mais espec&#237;fico e poderoso de risco de morte por doen&#231;a arterial coronariana (DAC) do que o colesterol total. Corti e cols.<sup>14</sup><sub>, </sub>a partir dos dados do EPESE, conclu&#237;ram que valores anormais de colesterol estavam ligados &#224; morte por DAC em idosos, sendo impr&#243;pria a sua exclus&#227;o dos trabalhos que analisam a rela&#231;&#227;o do colesterol com DCV. No <italic>The Northern Manhattan Study</italic><sup>15</sup> os autores inferiram que a HDL-c elevada est&#225; associada com riscos reduzidos de acidente vascular encef&#225;lico (AVE) isqu&#234;mico no idoso, considerando a HDL-c um importante e modific&#225;vel FR para AVE. Outro estudo relacionou o HDL-c baixo com o risco de mortalidade por DAC e AVE em idosos<sup>16</sup>. Por outro lado, no estudo PROSPER<sup>17</sup> n&#227;o foi altamente significativa a redu&#231;&#227;o de eventos vasculares, devendo existir cautela na an&#225;lise desses dados at&#233; que outros estudos confirmem esses benef&#237;cios. Entretanto, o estudo HPS<sup>18</sup> encontrou redu&#231;&#227;o de eventos vasculares maiores em pacientes com n&#237;veis elevados de HDL-c tratados com sinvastatina, quando comparados com placebo. </p>
    <p>Dessa forma, este estudo teve como objetivo avaliar as vari&#225;veis cl&#237;nicas e laboratoriais e a ocorr&#234;ncia de eventos CV fatais e n&#227;o-fatais, como: doen&#231;a arterial coronariana (angina, infarto agudo do mioc&#225;rdio e revasculariza&#231;&#227;o mioc&#225;rdica percut&#226;nea ou cir&#250;rgica); acidente vascular encef&#225;lico; acidente isqu&#234;mico transit&#243;rio (TIA); doen&#231;a de car&#243;tida; e insufici&#234;ncia card&#237;aca (IC), em idosos estratificados de acordo com o comportamento do HDL-c em seguimento de oito anos. </p>
    <p>
      <bold>M&#233;todo</bold>
    </p>
    <p>Para o presente estudo, foram avaliados 81 indiv&#237;duos acompanhados por 96,68 &#177; 11,57 meses, no ambulat&#243;rio do Hospital Universit&#225;rio Pedro Ernesto, divididos em tr&#234;s grupos, constitu&#237;dos pelo comportamento da HDL-c determinado na avalia&#231;&#227;o inicial (avalia&#231;&#227;o 1) e na segunda avalia&#231;&#227;o (avalia&#231;&#227;o 2), a saber:</p>
    <p>1. Grupo normal (GN), constitu&#237;do por indiv&#237;duos com valores da HDL-c normal, composto por 31 indiv&#237;duos, sendo 10 do sexo masculino (32,3%) e 21 do sexo feminino (67,7%).</p>
    <p>2. Grupo baixo (GB) com valores da HDL-c anormais (baixo), constitu&#237;do por 21 indiv&#237;duos, sendo 6 do sexo masculino (28,6%) e 15 do sexo feminino (71,4%)</p>
    <p>3. Grupo Vari&#225;vel (GV), com valores da HDL-c vari&#225;veis nas duas avalia&#231;&#245;es, formado por 29 indiv&#237;duos, sendo 15 do sexo masculino (51,7%) e 14 do sexo feminino (48,3%).</p>
    <p>Para a constitui&#231;&#227;o dos grupos, foram considerados os valores da HDL-c de acordo com as recomenda&#231;&#245;es da IV Diretriz Brasileira sobre Dislipidemia e Preven&#231;&#227;o da Aterosclerose<sup>19</sup>, sendo valores normais, aqueles iguais ou superiores a 40 mg/dl para o sexo masculino e iguais ou superiores a 50 mg/dl para o sexo feminino. Os valores abaixo desses pontos de corte foram considerados baixos, correspondendo a valores anormais.</p>
    <p>Os pacientes que concordaram em participar do estudo foram entrevistados e submetidos a exame cl&#237;nico e laboratorial. Da avalia&#231;&#227;o 1, cerca de oito anos antes, foram obtidos dados demogr&#225;ficos e epidemiol&#243;gicos, al&#233;m das condi&#231;&#245;es m&#233;dicas pregressas e dos medicamentos em uso. Para a avalia&#231;&#227;o 2, foram obtidos os mesmos dados, sendo dada &#234;nfase na identifica&#231;&#227;o de eventos CV fatais e n&#227;o-fatais, como: DAC (angina, infarto agudo do mioc&#225;rdio e revasculariza&#231;&#227;o mioc&#225;rdica percut&#226;nea ou cir&#250;rgica); AVE e TIA; doen&#231;a de car&#243;tida; dem&#234;ncia; e IC. Nos casos de &#243;bito, a causa foi apurada com an&#225;lise da documenta&#231;&#227;o m&#233;dica existente. </p>
    <p>A avalia&#231;&#227;o laboratorial incluiu a obten&#231;&#227;o dos valores de colesterol total (CT), dos triglicer&#237;deos (TG), e do HDL-c e LDL-c. Foram considerados normais os valores CT&lt; 200 mg/dl, LDL-c &lt; 130 mg/dl, e triglicer&#237;deos &lt; 150 mg/dl.</p>
    <p>Para a caracteriza&#231;&#227;o de doen&#231;a arterial coronariana foi considerada revasculariza&#231;&#227;o mioc&#225;rdica percut&#226;nea ou cir&#250;rgica, cintigrafia mioc&#225;rdica positiva<sup>20 </sup>e ecocardiograma com altera&#231;&#245;es de contratilidade bem definidas para coronariopatia<sup>21</sup>. Para a caracteriza&#231;&#227;o de evento vascular cerebral, foi considerada tomografia computadorizada cerebral ou resson&#226;ncia magn&#233;tica com altera&#231;&#245;es bem definidas para les&#227;o cerebral e ou d&#233;ficit motor, assim como para TIA, evento de perda de consci&#234;ncia ou d&#233;ficit motor transit&#243;rio bem documentado por atendimento hospitalar. A doen&#231;a vascular cerebral associada a dois d&#233;ficits cognitivos, sendo um a mem&#243;ria, foi considerada como dem&#234;ncia de acordo com o Manual Diagn&#243;stico e Estat&#237;stico de Transtornos Mentais, 4&#170; edi&#231;&#227;o<xref ref-type="fn" rid="nt"><sup>*</sup></xref>. Foi considerada doen&#231;a carot&#237;dea quando ao eco-Doppler fosse evidenciada a presen&#231;a de placas ateroscler&#243;ticas. Quaisquer outras intercorr&#234;ncias, como c&#226;ncer, hipotireoidismo, etc., foram consideradas como outros eventos.</p>
    <p>A press&#227;o arterial (PA) em repouso foi medida duas vezes durante a consulta, com intervalo de pelo menos cinco minutos, com o paciente na posi&#231;&#227;o sentada, sendo a m&#233;dia dessas leituras o valor adotado. A medida da PA e a sua classifica&#231;&#227;o foram realizadas de acordo com os crit&#233;rios do V DBHA<sup>22</sup>. </p>
    <p>A an&#225;lise estat&#237;stica foi feita utilizando-se o programa "SPSS for Windows", vers&#227;o 8.0.0. O teste de regress&#227;o log&#237;stica foi utilizado para avaliar a probabilidade de ocorr&#234;ncia ou n&#227;o de um evento. </p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Em rela&#231;&#227;o &#224; idade e ao tempo de acompanhamento, a compara&#231;&#227;o entre as m&#233;dias dos tr&#234;s grupos n&#227;o apresentou significado estat&#237;stico, bem como a distribui&#231;&#227;o por sexo (<xref ref-type="table" rid="tab01">tabela 1</xref>).</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt01.jpg"/></table-wrap>
    <p>A compara&#231;&#227;o das vari&#225;veis antropom&#233;tricas, metab&#243;licas e press&#243;ricas das avalia&#231;&#245;es 1 e 2 encontra-se descrita nas <xref ref-type="table" rid="tab02">tabelas 2</xref> e <xref ref-type="table" rid="tab03">3</xref>, respectivamente. Conforme pode se observar, em ambas as avalia&#231;&#245;es, apenas houve diferen&#231;a significativa na compara&#231;&#227;o das m&#233;dias de HDL-c e de TG, onde o grupo B apresentou m&#233;dias menores de HDL-c e valores maiores de TG quando comparados aos demais grupos. </p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt02.jpg"/></table-wrap>
    <table-wrap id="tab03">
      <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt03.jpg"/></table-wrap>
    <p>A compara&#231;&#227;o das m&#233;dias da press&#227;o arterial sist&#243;lica (PAS) e da press&#227;o arterial diast&#243;lica (PAD), nas duas avalia&#231;&#245;es (<xref ref-type="table" rid="tab02">tabelas 2</xref> e <xref ref-type="table" rid="tab03">3</xref>), n&#227;o mostrou diferen&#231;a estat&#237;stica significativa entre os tr&#234;s grupos, bem como a preval&#234;ncia de hipertens&#227;o arterial.</p>
    <p>
      <bold>An&#225;lise dos Eventos em Rela&#231;&#227;o &#224; HDL-c</bold>
    </p>
    <p>A <xref ref-type="table" rid="tab04">tabela 4</xref> mostra a distribui&#231;&#227;o de eventos nos tr&#234;s grupos em rela&#231;&#227;o ao comportamento da HDL-c. </p>
    <table-wrap id="tab04">
      <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt04.jpg"/></table-wrap>
    <p>O grupo com HDL-c baixo nas duas avalia&#231;&#245;es apresentou percentual significativamente maior de eventos CV que os outros dois grupos. Ocorreram 13 eventos CV no grupo normal (41,9%); 16 (76,2%) no grupo baixo; e 12 (41,4%) no grupo vari&#225;vel (&#967;<sup>2</sup>=7, 419; p=0,024). </p>
    <p>A <xref ref-type="table" rid="tab05">tabela 5</xref> mostra distribui&#231;&#227;o por tipos de eventos, demonstrando que n&#227;o houve diferen&#231;a entre os grupos quanto ao tipo de evento CV ocorrido. </p>
    <table-wrap id="tab05">
      <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt05.jpg"/></table-wrap>
    <p>A ocorr&#234;ncia de eventos em um modelo de regress&#227;o log&#237;stica foi considerada como vari&#225;vel dependente, e a idade, a PAS, a PAD, o colesterol, a HDL-c e os triglic&#233;rides obtidos na primeira avalia&#231;&#227;o, como vari&#225;veis independentes. Nesse modelo, apenas a idade e o HDL-c mantiveram correla&#231;&#227;o significativa com a ocorr&#234;ncia de eventos CV. Foi observado que quanto maior a idade, maior a ocorr&#234;ncia de eventos cardiovasculares (<italic>odds ratio</italic> = 1,187, p = 0,0230) e quanto menor a HDL-c, maior a ocorr&#234;ncia de eventos cardiovasculares (<italic>odds ratio</italic> = 0,9375, p = 0,0102) (<xref ref-type="table" rid="tab06">tabela 6</xref>).</p>
    <table-wrap id="tab06">
      <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt06.jpg"/></table-wrap>
    <p>A an&#225;lise da distribui&#231;&#227;o das mortes n&#227;o mostrou diferen&#231;a com valor estat&#237;stico significativo (&#967;<sup>2</sup>=1,359, p=0,507). </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Ao lado de uma maior expectativa de vida ao nascer, a incapacidade cr&#244;nica e a institucionaliza&#231;&#227;o t&#234;m mostrado tamb&#233;m maior preval&#234;ncia nos idosos, com predomin&#226;ncia no sexo feminino<sup>1</sup>. Como consequ&#234;ncia do aumento da preval&#234;ncia das doen&#231;as cr&#244;nico-degenerativas e suas sequelas, a depend&#234;ncia funcional representar&#225; um desafio adicional<sup>2</sup>. Em 2005, o gasto <italic>per capita</italic> da rede hospitalar do Sistema &#218;nico de Sa&#250;de (SUS) com homens de 60 a 69 anos foi mais do que quatro vezes superior ao gasto com homens de 30 a 39 anos, mas apenas a metade do valor do grupo com 80 anos ou mais<sup>23</sup>.</p>
    <p>A magnitude das mudan&#231;as demogr&#225;ficas e epidemiol&#243;gicas exige a urgente ado&#231;&#227;o de uma pol&#237;tica assistencial ao idoso<sup>23</sup>. A expectativa de sa&#250;de &#233; mais importante que a pr&#243;pria expectativa de vida, constituindo um desafio levantado pela Organiza&#231;&#227;o mundial de Sa&#250;de: "Como prevenir e postergar a doen&#231;a e a incapacidade, mantendo a sa&#250;de, a independ&#234;ncia e a mobilidade da popula&#231;&#227;o que envelhece?"<sup>1</sup>.</p>
    <p>A DCV &#233; a principal causa de morte e de incapacidade nas pessoas acima de 65 anos, a despeito do progressivo decl&#237;nio das DCV na popula&#231;&#227;o desde a d&#233;cada de 70. As medidas preventivas para as DCV, consequentemente, adquirem especial destaque<sup>1,24</sup>. A DCV tem um importante impacto sobre a expectativa de vida, al&#233;m de contribuir para a piora da qualidade de vida, levando &#224; perda da independ&#234;ncia e &#224; institucionaliza&#231;&#227;o.</p>
    <p>Numerosos estudos t&#234;m abordado a influ&#234;ncia dos FR na g&#234;nese da aterosclerose<sup>25-28</sup>, entretanto, a literatura apresenta resultados controversos em rela&#231;&#227;o ao valor preditivo de alguns fatores de risco para DCV nos idosos, principalmente ap&#243;s os 75 anos<sup>29,30</sup>. O surgimento de estudos sobre os fatores de risco para a aterosclerose, com desenho adequado ao idoso trouxe novos fatos &#224; luz<sup>30</sup>, embora os resultados ainda apresentem algumas discord&#226;ncias entre si.</p>
    <p>Diversos trabalhos t&#234;m considerado o envelhecimento como um dos mais importantes FR independente para morbidade e mortalidade por DCV, sendo o endot&#233;lio vascular um evidente &#243;rg&#227;o alvo<sup>25,28,31</sup>. Luscher e Barton<sup>31</sup> estudaram a influ&#234;ncia da idade, da HA e dos l&#237;pides sobre o endot&#233;lio vascular, e observaram que todas as tr&#234;s condi&#231;&#245;es se encontravam relacionadas &#224;s altera&#231;&#245;es funcionais do endot&#233;lio, podendo contribuir para a prolifera&#231;&#227;o vascular, trombose, vasoespasmo e isquemia. Dentro do contexto dos fatores de risco, este estudo foi projetado para estabelecer a import&#226;ncia da HDL-c para a ocorr&#234;ncia da DCV no idoso.</p>
    <p>Inicialmente, foi realizada a compara&#231;&#227;o das vari&#225;veis epidemiol&#243;gicas entre os tr&#234;s grupos. A avalia&#231;&#227;o das m&#233;dias para a idade, para o sexo e para o tempo de acompanhamento mostrou homogeneidade entre os tr&#234;s grupos sem diferen&#231;a estat&#237;stica significativa e, dessa forma, n&#227;o tiveram influ&#234;ncia na an&#225;lise dos eventos.</p>
    <p>Os &#237;ndices antropom&#233;tricos utilizados foram: o peso, a altura e o &#237;ndice de massa corp&#243;rea (IMC), utilizado por guardar uma boa correla&#231;&#227;o com a medida direta da gordura corporal.No presente estudo, n&#227;o houve diferen&#231;as entre os grupos quanto &#224;s m&#233;dias das vari&#225;veis antropom&#233;tricas analisadas, o que est&#225; em acordo com o estudo de Price, onde o IMC n&#227;o foi associado positivamente &#224; mortalidade circulat&#243;ria em homens e em mulheres<sup>32</sup>. </p>
    <p>As m&#233;dias da PAS e da PAD n&#227;o mostraram diferen&#231;as estat&#237;sticas entre os tr&#234;s grupos em ambas as avalia&#231;&#245;es, n&#227;o interferindo com os resultados. Uma an&#225;lise recente do <italic>Framingham Heart Study</italic> mostrou que o ac&#250;mulo de FR, entre eles a HA, contribui para menor sobrevida e maior incapacidade em idosos<sup>33</sup>. Os efeitos da HA sobre a morbi-mortalidade CV encontram-se bem estabelecidos<sup>34</sup>. Neste estudo, a PA, avaliada em modelo de regress&#227;o log&#237;stica, n&#227;o mostrou rela&#231;&#227;o estatisticamente significativa com a ocorr&#234;ncia de eventos cardiovasculares. </p>
    <p>As vari&#225;veis metab&#243;licas foram determinadas na fase inicial do trabalho, na avalia&#231;&#227;o 1, e reavaliadas pelo menos cinco anos ap&#243;s, na avalia&#231;&#227;o 2, correlacionando-as aos eventos encontrados. </p>
    <p>Os n&#237;veis elevados de colesterol total e de LDL-c t&#234;m se mostrado como importantes fatores de risco para a incid&#234;ncia e mortalidade total por DCV em indiv&#237;duos de meia idade em diversos estudos prospectivos, incluindo o <italic>Honolulu Heart Program</italic> (HHP)<sup>18</sup>, entretanto, esses achados nos idosos t&#234;m sido menos consistentes. No HHP, a propor&#231;&#227;o de redu&#231;&#227;o na taxa de eventos foi similar em jovens e idosos acima de 70 anos. Nos resultados obtidos no presente estudo, n&#227;o houve rela&#231;&#227;o entre DCV colesterol total e LDL-c em idosos.</p>
    <p>A an&#225;lise das m&#233;dias encontradas para o colesterol na avalia&#231;&#227;o 1 mostrou valores mais altos em rela&#231;&#227;o aos valores obtidos na avalia&#231;&#227;o 2 em todos os grupos, portanto, valores menores foram obtidos nos indiv&#237;duos com mais idade. Essa observa&#231;&#227;o se encontra de acordo com a literatura atual, que refere queda na preval&#234;ncia de perfil lip&#237;dico anormal com a idade<sup>24</sup>. Por outro lado, a utiliza&#231;&#227;o de medicamentos espec&#237;ficos para o tratamento de dislipidemia poderia tamb&#233;m contribuir para a mudan&#231;a observada. Al&#233;m disso, alguns estudos epidemiol&#243;gicos sugerem que a rela&#231;&#227;o entre a DAC e os n&#237;veis de colesterol sofre decl&#237;nio com a idade, gerando a cren&#231;a de que haveria menor benef&#237;cio no tratamento do colesterol nos idosos<sup>24,35,36</sup>. Entretanto, alguns estudos mostram resultados positivos no que diz respeito ao tratamento, como ocorreu no <italic>Heart Protection Study</italic><sup>18</sup>, onde havia um subgrupo de pacientes com idade superior a 70 anos, cuja maioria n&#227;o excedeu os 75 anos, havendo redu&#231;&#227;o no risco vascular. </p>
    <p>Ap&#243;s a utiliza&#231;&#227;o de um modelo de regress&#227;o log&#237;stica onde a ocorr&#234;ncia de eventos foi considerada como vari&#225;vel dependente, e idade, PAS, PAD, CT, HDL-c e TG como vari&#225;veis independentes na avalia&#231;&#227;o 1, o colesterol n&#227;o se mostrou associado significativamente para o desenvolvimento de eventos cardiovasculares. </p>
    <p>As m&#233;dias dos triglic&#233;rides foram significativamente diferentes nas duas avalia&#231;&#245;es. Neste estudo, os n&#237;veis mais elevados de triglic&#233;rides ocorreram no grupo com HDL-c mais baixo, tanto na avalia&#231;&#227;o 1 como na avalia&#231;&#227;o 2, de acordo com a estreita liga&#231;&#227;o entre o transporte reverso de colesterol, o HDL-c e os triglic&#233;rides<sup>37,38</sup>. Por&#233;m, em um modelo de regress&#227;o log&#237;stica a vari&#225;vel triglic&#233;rides n&#227;o mostrou rela&#231;&#227;o significativa com a DCV. Embora an&#225;lises univariadas de estudos epidemiol&#243;gicos tenham demonstrado que a hipertrigliceridemia est&#225; associada com um aumento de DAC em homens e mulheres, an&#225;lises multivariadas t&#234;m mostrado resultados conflitantes para a caracteriza&#231;&#227;o dos triglic&#233;rides como fator independente de risco para DAC, parecendo ser um fator mais importante para novos eventos na mulher do que nos homens<sup>8</sup>. </p>
    <p>O modelo de regress&#227;o log&#237;stica mostrou que quanto maior a idade maior a ocorr&#234;ncia de eventos CV (<italic>odds ratio</italic> = 1,187, p = 0,0230), de acordo com a literatura que refere a rela&#231;&#227;o direta entre mortalidade CV e idade<sup>38</sup>. </p>
    <p>O comportamento do HDL-c mostrou express&#227;o estat&#237;stica para ocorr&#234;ncia de eventos (&#967;<sup>2</sup>=7,419, p=0,024). Na an&#225;lise do modelo de regress&#227;o log&#237;stica, essa rela&#231;&#227;o foi mantida, mostrando que quanto maior a HDL-c menor a ocorr&#234;ncia de eventos CV. </p>
    <p>A HDL-c tem sido identificada como fator de risco maior e independente, com rela&#231;&#227;o mais importante para o desenvolvimento de DAC do que o colesterol total e a LDL-c<sup>39</sup>. Outro aspecto que tem sido demonstrado &#233; o valor preditivo para DAC da HDL-c baixa, maior na mulher do que no homem<sup>38</sup>.</p>
    <p>Tem-se tentado explicar os efeitos antiaterog&#234;nicos da HDL-c por suas propriedades anti-inflamat&#243;rias, antioxidantes, antiagregantes, anticoagulantes e pr&#243;-fibrinol&#237;ticas, que promovem a manuten&#231;&#227;o das fun&#231;&#245;es endoteliais. Assim, os n&#237;veis baixos de HDL-c contribuiriam para o aumento da DCV pela perda dos efeitos antiaterog&#234;nicos, devido ao menor transporte reverso do colesterol, menor a&#231;&#227;o anti-inflamat&#243;ria e perda das propriedades antitromb&#243;ticas.</p>
    <p>Frequentemente, s&#227;o observados baixos n&#237;veis de HDL-c em pacientes com DAC, enquanto, com frequ&#234;ncia, s&#237;ndromes gen&#233;ticas que cursam com HDL-c elevado est&#227;o associadas &#224;s redu&#231;&#245;es de ocorr&#234;ncia de DAC e maior longevidade<sup>40</sup>. O interesse sobre a HDL-c tornou-se mais forte por esta ser encontrada frequentemente em associa&#231;&#227;o com n&#237;veis elevados de lipoprote&#237;nas aterog&#234;nicas, inclusive VLDL, LDL-c do tipo pequenas e densas, e tamb&#233;m com s&#237;ndrome metab&#243;lica, envolvendo resist&#234;ncia &#224; insulina, intoler&#226;ncia &#224; glicose e hipertens&#227;o arterial<sup>40</sup>. A complexidade do metabolismo das HDL-c ainda necessita de outros estudos.</p>
    <p>A ocorr&#234;ncia elevada de eventos nos tr&#234;s grupos poderia estar relacionada &#224; rela&#231;&#227;o direta de eventos e de mortalidade com a idade e com o tempo de exposi&#231;&#227;o aos FR<sup>33</sup>, de forma que no grupo de HDL-c baixo, somente 23,8% n&#227;o apresentaram algum evento. Entretanto, n&#227;o houve predom&#237;nio de nenhum tipo espec&#237;fico de evento CV relacionado ao comportamento da HDL-c.</p>
    <p>Ressalta-se que este estudo tem o car&#225;ter de observa&#231;&#227;o longitudinal, com tempo prolongado de acompanhamento &#150; oito anos - e tem como principal contribui&#231;&#227;o a demonstra&#231;&#227;o da correla&#231;&#227;o significativa do HDL-c persistentemente baixo com a ocorr&#234;ncia de eventos CV.</p>
    <p>Este estudo apresenta limita&#231;&#245;es decorrentes do n&#250;mero relativamente pequeno de pacientes acompanhados e n&#227;o &#233; aconselh&#225;vel haver generaliza&#231;&#227;o dos seus resultados, apesar de seus importantes achados. Os desfechos avaliados n&#227;o s&#227;o todos considerados maiores, entretanto, podem caracterizar de forma bastante aceit&#225;vel a presen&#231;a de doen&#231;a ateroscler&#243;tica significativa e a ocorr&#234;ncia de eventos cardiovasculares numa amostra de idosos acompanhada prospectivamente. Al&#233;m disso, essas condi&#231;&#245;es apresentam grande repercuss&#227;o sobre a qualidade de vida, que se constituiu em um dos principais objetivos da abordagem de popula&#231;&#245;es desta faixa et&#225;ria. </p>
    <p>Em conclus&#227;o, a ocorr&#234;ncia de valores de HDL-c permanentemente baixos em idosos, ao longo de oito anos de acompanhamento, associou-se a maiores n&#237;veis de triglic&#233;rides nas duas avalia&#231;&#245;es, mas n&#227;o se relacionou &#224; press&#227;o arterial, &#237;ndices antropom&#233;tricos e LDL-c. A idade e a presen&#231;a de HDL-c com dosagens permanentemente baixas foram fatores de risco para o desenvolvimento de eventos cardiovasculares, enquanto o colesterol total e a press&#227;o arterial n&#227;o mostraram rela&#231;&#227;o significativa. Os dados deste estudo enfatizam a necessidade de avalia&#231;&#227;o do perfil lip&#237;dico tamb&#233;m em idosos, para identificar pacientes com maior risco potencial para doen&#231;a CV.</p>
    <p>
      <bold>Agradecimentos</bold>
    </p>
    <p>Os autores agradecem &#224; Simone Offrede, bi&#243;loga do Hospital Universit&#225;rio Pedro Ernesto, respons&#225;vel pela coleta das amostragens sangu&#237;neas, bem como pelo controle de chamada dos pacientes.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Elizabete Viana de Freitas pelo Hospital Universit&#225;rio Pedro Ernesto da Universidade do Rio de Janeiro.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Elizabete Viana de Freitas </p>
        <p> Rua Almirante Benjamim Sodr&#233; 40/702, Laranjeiras </p>
        <p> 22.240-080, Rio de Janeiro, RJ, Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="elizabet@rio.com.br">elizabet@rio.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 15/09/08; revisado recebido em 21/10/08; aprovado 13/11/08.</p>
    <p>
      <fn id="nt">
        <label>*</label>
        <p>Manual diagn&#243;stico e estat&#237;stico de transtornos mentais. 4&#170; ed. Porto Alegre: Artes M&#233;dicas; 2002.</p>
      </fn>
    </p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. World Health Organization (WHO). Global survey on geriatrics in the medical curriculum: a collaborative study of WHO and the International Federation of Medical Students' Association. Genebra; 2002.</mixed-citation>
        <element-citation publication-type="book">
          <source>Global survey on geriatrics in the medical curriculum: a collaborative study of WHO and the International Federation of Medical Students' Association</source>
          <date>
            <year>2002</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. IDB 2006 Brasil. [Acesso em 2008 Ago 5]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://tabnet.datasus.gov.br/cgi/idb2006/matriz.htm">http://tabnet.datasus.gov.br/cgi/idb2006/matriz.htm</ext-link></mixed-citation>
        <element-citation publication-type="webpage">
          <comment>Available at:<ext-link ext-link-type="uri" xlink:href="http://http://tabnet.datasus.gov.br/cgi/idb2006/matriz.htm">link</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3.  Chaimowicz F. Epidemiologia e o envelhecimento no Brasil. In: Freitas EV, Py L,  Can&#231;ado FAX (eds). Tratado de geriatria e gerontologia. 2&#350;. ed. Rio de  Janeiro: Guanabara-Koogan; 2006.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de geriatria e gerontologia</source>
          <date>
            <year>2006</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Chaimowicz</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Py</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Can&#231;ado</surname>
              <given-names>FAX</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4.  Willians MA, Fleg JL, Ades PA, Bernard RC, Miller NH, Mohiuddin SM, et al. Secondary  prevention of coronary heart disease in the elderly (With emphasis on patients  <underline>&gt;</underline> 75 years of age). An American Heart Association Scientific Statement  from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation  and Prevention. Circulation. 2002; 105 (14): 1735-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Secondary prevention of coronary heart disease in the elderly (With emphasis on patients &gt; 75 years of age). An American Heart Association Scientific Statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation and Prevention</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1735</fpage>
          <lpage>43</lpage>
          <issue>14</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Willians</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Fleg</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Ades</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Bernard</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Mohiuddin</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5.  Wong ND, Ridker PM. Thrombosis inflammation and infection. In: Wong ND, Black  HR, Gardin JM (eds). Preventive cardiology. New York: McGraw-Hill; 2000. p.  269-89.</mixed-citation>
        <element-citation publication-type="book">
          <source>Preventive cardiology</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>269</fpage>
          <lpage>89</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Ridker</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Gardin</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Bilato C, Crow MT. Atherosclerosis  and the vascular biology of aging. Aging (Milano). 1996; 8 (4): 222-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Atherosclerosis and the vascular biology of aging</article-title>
          <source>Aging (Milano)</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>222</fpage>
          <lpage>4</lpage>
          <issue>4</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bilato</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Crow</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7.  Libby P. A biologia vascular da aterosclerose. In: Braunwald E. Tratado de doen&#231;as  cardiovasculares. 7&#350; ed. Rio de Janeiro: Elsevier; 2006. p. 921-7.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de doen&#231;as cardiovasculares</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>921</fpage>
          <lpage>7</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8.  Aronow WS. Cholesterol and coronary artery disease- do we treat low HDL cholesterol  or high triglycerides?. Geriatrics Aging. 2002; 5 (2): 24-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cholesterol and coronary artery disease- do we treat low HDL cholesterol or high triglycerides?.</article-title>
          <source>Geriatrics Aging</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>24</fpage>
          <lpage>6</lpage>
          <issue>2</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Aronow</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9.  Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of  coronary disease in 1793 men and women aged <underline>&gt;</underline>62 years. Am J Cardiol.  1994; 73 (9): 702-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Correlation of serum lipids with the presence or absence of coronary disease in 1793 men and women aged &gt;62 years</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>702</fpage>
          <lpage>3</lpage>
          <issue>9</issue>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Aronow</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Mackness  MI, Durrington PN, Mackness B. How high-density lipoprotein protects against  the effect of lipid peroxidation. Curr Opin Lipidol. 2000; 11 (4): 383-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>How high-density lipoprotein protects against the effect of lipid peroxidation</article-title>
          <source>Curr Opin Lipidol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>383</fpage>
          <lpage>8</lpage>
          <issue>4</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mackness</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Durrington</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Mackness</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Rader DJ. Regulation of reverse  cholesterol transport and clinical implications. Am J Cardiol. 2003; 92 (4A):  42J-49J.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Regulation of reverse cholesterol transport and clinical implications</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>42J</fpage>
          <lpage>49J</lpage>
          <issue>4A</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rader</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Wilson P, D'Agostino  R, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart  disease using risk factors (Framingham study). Circulation. 1998; 97 (18): 1837-47.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prediction of coronary heart disease using risk factors (Framingham study)</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1837</fpage>
          <lpage>47</lpage>
          <issue>18</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>D'Agostino</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Belanger</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Silbershatz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13.  Cornoni-Huntley J, Ostfeld AM, Taylor J, Wallace RB, Blazer D, Berkman LF,  et al. Established populations for epidemiologic studies of the elderly (EPSE):  study design and methodology. Aging (Milano). 1993; 5 (1): 27-37.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Established populations for epidemiologic studies of the elderly (EPSE): study design and methodology</article-title>
          <source>Aging (Milano)</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>27</fpage>
          <lpage>37</lpage>
          <issue>1</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cornoni-Huntley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ostfeld</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Blazer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Berkman</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14.  Corti MC, Guralnik JM, Salive M, Harris T, Ferrucci L, Glynn RJ, et al. Clarifying  the direct relation between total cholesterol levels and death from coronary heart  disease in older persons. Ann Intern Med. 1997; 126 (10): 753-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>753</fpage>
          <lpage>60</lpage>
          <issue>10</issue>
          <volume>126</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Corti</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Guralnik</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Salive</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ferrucci</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Glynn</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15.  Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin I-F, et al.  High-density lipoprotein cholesterol and ischemic stroke in the elderly (the  Northern Manhattan Stroke Study). JAMA. 2001; 285 (21): 2729-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>High-density lipoprotein cholesterol and ischemic stroke in the elderly (the Northern Manhattan Stroke Study)</article-title>
          <source>JAMA</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2729</fpage>
          <lpage>35</lpage>
          <issue>21</issue>
          <volume>285</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sacco</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Benson</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Kargman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Boden-Albala</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tuck</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lin I-F</surname>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16.  Weverling-Rijnsburger AWE, Jonkers IJAM, Exel E, Gussekloo J, Westendorp RGJ.  High-density vs low-density lipoprotein cholesterol as the risk factor  for coronary artery disease and stroke in old age. Arch Intern Med. 2003; 163  (13): 1549-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1549</fpage>
          <lpage>54</lpage>
          <issue>13</issue>
          <volume>163</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weverling-Rijnsburger</surname>
              <given-names>AWE</given-names>
            </name>
            <name>
              <surname>Jonkers</surname>
              <given-names>IJAM</given-names>
            </name>
            <name>
              <surname>Exel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gussekloo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Westendorp</surname>
              <given-names>RGJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Shepherd J,  Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, et al on behalf of the PROSPER  Study Group. The design of a prospective study of pravastatin in the elderly at  risk (PROSPER). Am J Cardiol. 1999; 84 (10): 1192-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The design of a prospective study of pravastatin in the elderly at risk (PROSPER)</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1192</fpage>
          <lpage>7</lpage>
          <issue>10</issue>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shepherd</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Blauw</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Cobbe</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Bollen</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18.  MRC / BHF. Heart Protection Study Collaborative Group. Heart Protection Study  of cholesterol lowering with simvastatin in 20.536 high-risk individuals:  a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart Protection Study Collaborative Group. Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial</article-title>
          <source>Lancet</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>7</fpage>
          <lpage>22</lpage>
          <volume>360</volume>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19.  Sociedade Brasileira de Cardiologia. IV Diretrizes brasileiras sobre dislipidemias.  Arq Bras Cardiol. 2007; 88 (supl. 1): 2-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>IV Diretrizes brasileiras sobre dislipidemias</article-title>
          <source>Arq Bras Cardiol.</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2</fpage>
          <lpage>19</lpage>
          <issue>1</issue>
          <volume>88</volume>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20.  Sociedade Brasileira de Cardiologia. I Diretriz brasileira sobre cardiologia nuclear  (Atualiza&#231;&#227;o). Arq Bras Cardiol. 2006; 86 (supl 4): 4-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Diretriz brasileira sobre cardiologia nuclear (Atualiza&#231;&#227;o)</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>4</fpage>
          <lpage>35</lpage>
          <volume>86</volume>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21.  Sociedade Brasileira de Cardiologia. Diretriz para indica&#231;&#245;es e  utiliza&#231;&#227;o da ecocardiografia na pr&#225;tica cl&#237;nica.  Arq Bras Cardiol. 2004; 82 (supl 2): 1-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diretriz para indica&#231;&#245;es e utiliza&#231;&#227;o da ecocardiografia na pr&#225;tica cl&#237;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1</fpage>
          <lpage>34</lpage>
          <volume>82</volume>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22.  Sociedade Brasileira de Cardiologia. Sociedade Brasileira de Hipertens&#227;o.  Sociedade Brasileira de Nefrologia. V Diretrizes brasileiras de hipertens&#227;o  arterial. Rev Bras Hipertens. 2006; 13 (4): 256-312.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>V Diretrizes brasileiras de hipertens&#227;o arterial</article-title>
          <source>Rev Bras Hipertens.</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>256</fpage>
          <lpage>312</lpage>
          <issue>4</issue>
          <volume>13</volume>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation>23. Minist&#233;rio da Sa&#250;de. DATASUS: Sistema de informa&#231;&#245;es sobre sa&#250;de. Bras&#237;lia; 2006.</mixed-citation>
        <element-citation publication-type="book">
          <source>DATASUS: Sistema de informa&#231;&#245;es sobre sa&#250;de</source>
          <date>
            <year>2006</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24.  Fitchett D. Lipid management: who screen? who to treat? Geriatrics Aging. 2005,  8 (10): 21-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Lipid management: who screen? who to treat?</article-title>
          <source>Geriatrics Aging</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>21</fpage>
          <lpage>8</lpage>
          <issue>10</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fitchett</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. McLaughlin MA.  The aging heart: state-of-the-art prevention and management of cardiac  disease. Geriatrics. 2001; 56 (6): 45-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The aging heart: state-of-the-art prevention and management of cardiac disease</article-title>
          <source>Geriatrics</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>45</fpage>
          <lpage>9</lpage>
          <issue>6</issue>
          <volume>56</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McLaughlin</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26.  Freitas EV. Atividade f&#237;sica na terceira idade. In: Oliveira MAB, N&#243;brega  ACL. (orgs.). T&#243;picos especiais em medicina do esporte. Rio de Janeiro:  Atheneu; 2003. p. 121-42.</mixed-citation>
        <element-citation publication-type="book">
          <source>T&#243;picos especiais em medicina do esporte</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>121</fpage>
          <lpage>42</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Freitas</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>MAB</given-names>
            </name>
            <name>
              <surname>N&#243;brega</surname>
              <given-names>ACL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Garcia-Palmieri  MR. Cardiovascular disease prevention in the elderly. Clinical Geriatrics. 2001;  9 (5): 69-77.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular disease prevention in the elderly</article-title>
          <source>Clinical Geriatrics</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>69</fpage>
          <lpage>77</lpage>
          <issue>5</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Palmieri</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Kannel WB. Coronary  heart disease risk factors in the elderly. Am J Geriatr Cardiol. 2002; 11 (2):  101-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coronary heart disease risk factors in the elderly</article-title>
          <source>Am J Geriatr Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>101</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Wilson PW, Anderson  KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol  and HDL-c with age: the Framingham Study. J Gerontol. 1994; 49 (6): 252-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Determinants of change in total cholesterol and HDL-c with age: the Framingham Study</article-title>
          <source>J Gerontol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>252</fpage>
          <lpage>7</lpage>
          <issue>6</issue>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Castelli</surname>
              <given-names>WP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30.  Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially  modifiable risk factors associate with myocardial infarction in 52 countries (the  INTERHEART study). Lancet. 2004; 364: 937-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of potentially modifiable risk factors associate with myocardial infarction in 52 countries (the INTERHEART study)</article-title>
          <source>Lancet</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>937</fpage>
          <lpage>52</lpage>
          <volume>364</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hawken</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ounpuu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dans</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Avezum</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lanas</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31.  Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol. 1997; 20 (11 Suppl  2): II3-II10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Biology of the endothelium</article-title>
          <source>Clin Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>II3</fpage>
          <lpage>II10</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Luscher</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Price G M, Uauy  R, Breeze E, Bulpitt C J, Fletcher A E. Weight, shape, and mortality risk in older  persons: elevated waist-hip ratio, not high body mass index, is associated  with a greater risk of mortality. Am J Clin Nutr. 2006; 84 (2): 449-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of mortality</article-title>
          <source>Am J Clin Nutr</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>449</fpage>
          <lpage>60</lpage>
          <issue>2</issue>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Price G</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uauy</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Breeze</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bulpitt C</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fletcher A</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33.  Terry DF, Pencina MJ, Vasan RS, Murabito JM, Wolf PA, Hayes MK, et al. Cardiovascular  risk factors predictive for survival and morbidity-free survival in the oldest-old  Framingham Heart Study participants. J Am Geriatr Soc. 2005; 53 (11): 1944-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular risk factors predictive for survival and morbidity-free survival in the oldest-old Framingham Heart Study participants</article-title>
          <source>J Am Geriatr Soc</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1944</fpage>
          <lpage>50</lpage>
          <issue>11</issue>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Terry</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Pencina</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Vasan</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Murabito</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34.  Juva K, Rastas S, Pirttij&#228; T. Blood pressure and survival in the very old.  Geriatrics Aging. 2007; 10 (9): 572-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Blood pressure and survival in the very old</article-title>
          <source>Geriatrics Aging</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>572</fpage>
          <lpage>7</lpage>
          <issue>9</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Juva</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rastas</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pirttij&#228;</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35.  Burchfiel C, Laws A, Benfante R, Goldberg R, Hwang L, Chiu D, et al. Combined  effects of hdl cholesterol, triglyceride, and total cholesterol concentrations  on 18-year risk of atherosclerotic disease. Circulation. 1995; 92 (6): 1430-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Combined effects of hdl cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease</article-title>
          <source>Circulation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1430</fpage>
          <lpage>6</lpage>
          <issue>6</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Burchfiel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Benfante</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chiu</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36.  Houterman S, Verschuren WM, Hofman A, Witteman JC. Serum cholesterol is a risk  factor for myocardial infarction in elderly men and women: the Rotterdam study.  J Intern Med. 1999; 246 (1): 25-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam study</article-title>
          <source>J Intern Med</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>25</fpage>
          <lpage>33</lpage>
          <issue>1</issue>
          <volume>246</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Houterman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Verschuren</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Hofman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Witteman</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37.  Tall AR, Jiang X-C, Luo YT, Silver D. 1999 George Lyman Duff Memorial Lecture:  Lipid transfer/proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb  Vasc Biol. 2000; 20 (5): 1185-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>1999 George Lyman Duff Memorial Lecture: Lipid transfer/proteins, HDL metabolism, and atherogenesis</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1185</fpage>
          <lpage>8</lpage>
          <issue>5</issue>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tall</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Jiang X-C</surname>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Silver</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38.  Cardenas GA, Lavie CJ, Milani RV. Importance and mangement of low levels of high-density  lipoprotein cholesterol in older adults. Part I: role and mechanism. Geriatrics  Aging. 2004; 7 (3): 40-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Importance and mangement of low levels of high-density lipoprotein cholesterol in older adults. Part I: role and mechanism</article-title>
          <source>Geriatrics Aging</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>40</fpage>
          <lpage>4</lpage>
          <issue>3</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cardenas</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Lavie</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Milani</surname>
              <given-names>RV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Cardenas  GA, Lavie CJ, Milani RV. Importance and mangement of low levels of high-density  lipoprotein cholesterol in older adults. Part II: screening and treatment. Geriatrics  Aging. 2004; 7 (4): 41-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Importance and mangement of low levels of high-density lipoprotein cholesterol in older adults. Part II: screening and treatment</article-title>
          <source>Geriatrics Aging</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>41</fpage>
          <lpage>8</lpage>
          <issue>4</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cardenas</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Lavie</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Milani</surname>
              <given-names>RV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Rader  DJ. High-density lipoprotein cholesterol and atherosclerosis. Am J Cardiol.  2002; 90 (8A): 62i-70i.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>High-density lipoprotein cholesterol and atherosclerosis</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>62i</fpage>
          <lpage>70i</lpage>
          <issue>8A</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rader</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">La importancia del HDL-c para la ocurrencia de la enfermedad cardiovascular en el adulto mayor</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: Estudios sobre el impacto del HDL-c y ocurrencia de enfermedad cardiovascular (CV) en adultos mayores son raros. OBJETIVO: Evaluar las variables cl&#237;nicas y laboratoriales y la ocurrencia de eventos CV en adultos mayores estratificados seg&#250;n el comportamiento del HDL-c en seguimiento de ocho a&#241;os. M&#201;TODOS: Se evaluaron, en dos momentos (A1 y A2), con espacio m&#237;nimo de cinco a&#241;os, a 81 adultos mayores, con edad promedio de 68,51 &#177; 6,32 (el 38,2% del sexo masculino). Los individuos fueron divididos en 3 grupos de acuerdo con el nivel de HDL-c: HDL-c normal en las dos evaluaciones (GN) (n=31); HDL-c bajo en las dos evaluaciones (GB) (n=21); y HDL-c variable de A1 para A2 (GV) (n=29). Se registraron los eventos CV mayores: enfermedad coronaria (angina, infarto miocardio, revascularizaci&#243;n mioc&#225;rdica percut&#225;nea/quir&#250;rgica), accidente vascular encef&#225;lico, accidente isqu&#233;mico transitorio, enfermedad carot&#237;dea, demencia e insuficiencia cardiaca. RESULTADOS: Los grupos no difirieron en cuanto su edad y el sexo en A1 y A2. Los promedios de los triglic&#233;ridos fueron menores en el GN en A1 (p=0,027) y A2 (p=0,016) que en el GB. Sin embargo la distribuci&#243;n de eventos CV fue de 13 en el GN (41,9%), 16 (76,2%) en el GB y de 12 (41,4%) en el GV (&#967;2=7,149, p=0,024). En el an&#225;lisis de regresi&#243;n log&#237;stica se pudo observar que cuanto mayor la edad (OR=1,187, p=0,0230) y cuanto menor el HDL-c (OR=0,9372, p=0,0102), mayor la ocurrencia de eventos CV. CONCLUSI&#211;N: El HDL-c permanentemente bajo a lo largo de ocho a&#241;os de seguimiento fue el factor de riesgo para desarrollo de eventos CV en adultos mayores.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Colesterol HDL</kwd>
        <kwd>salud del adulto mayor</kwd>
        <kwd>enfermedades cardiovasculares</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="tx-body2">
          <label>
            <bold>La importancia del HDL-c para la ocurrencia de la enfermedad cardiovascular en el adulto mayor</bold>
          </label>
          <p>
            <bold>Elizabete Viana de Freitas; Andr&#233;a Ara&#250;jo Brand&#227;o; Roberto Pozzan; Maria Eliane Magalh&#227;es; Fl&#225;via Fonseca; Oswaldo Pizzi; &#201;rika Campana; Ayrton Pires Brand&#227;o</bold>
          </p>
        </fn>
      </p>
      <p>Hospital Universit&#225;rio Pedro Ernesto, UERJ, Rio de Janeiro, RJ - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> Estudios sobre el impacto del HDL-c y ocurrencia de enfermedad cardiovascular (CV) en adultos mayores son raros.</p>
      <p><bold>OBJETIVO:</bold> Evaluar las variables cl&#237;nicas y laboratoriales y la ocurrencia de eventos CV en adultos mayores estratificados seg&#250;n el comportamiento del HDL-c en seguimiento de ocho a&#241;os.</p>
      <p><bold>M&#201;TODOS:</bold> Se evaluaron, en dos momentos (A1 y A2), con espacio m&#237;nimo de cinco a&#241;os, a 81 adultos mayores, con edad promedio de 68,51 &#177; 6,32 (el 38,2% del sexo masculino). Los individuos fueron divididos en 3 grupos de acuerdo con el nivel de HDL-c: HDL-c normal en las dos evaluaciones (GN) (n=31); HDL-c bajo en las dos evaluaciones (GB) (n=21); y HDL-c variable de A1 para A2 (GV) (n=29). Se registraron los eventos CV mayores: enfermedad coronaria (angina, infarto miocardio, revascularizaci&#243;n mioc&#225;rdica percut&#225;nea/quir&#250;rgica), accidente vascular encef&#225;lico, accidente isqu&#233;mico transitorio, enfermedad carot&#237;dea, demencia e insuficiencia cardiaca.</p>
      <p><bold>RESULTADOS:</bold> Los grupos no difirieron en cuanto su edad y el sexo en A1 y A2. Los promedios de los triglic&#233;ridos fueron menores en el GN en A1 (p=0,027) y A2 (p=0,016) que en el GB. Sin embargo la distribuci&#243;n de eventos CV fue de 13 en el GN (41,9%), 16 (76,2%) en el GB y de 12 (41,4%) en el GV (&#967;<sup>2</sup>=7,149, p=0,024). En el an&#225;lisis de regresi&#243;n log&#237;stica se pudo observar que cuanto mayor la edad (OR=1,187, p=0,0230) y cuanto menor el HDL-c (OR=0,9372, p=0,0102), mayor la ocurrencia de eventos CV.</p>
      <p><bold>CONCLUSI&#211;N:</bold> El HDL-c permanentemente bajo a lo largo de ocho a&#241;os de seguimiento fue el factor de riesgo para desarrollo de eventos CV en adultos mayores.</p>
      <p><bold>Palabras clave: </bold> Colesterol HDL / salud del adulto mayor, enfermedades cardiovasculares.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>En todo el mundo, el contingente de personas con edad igual o superior a 60 a&#241;os viene creciendo r&#225;pidamente<sup>1</sup>. Brasil presenta el 10,5 % de su poblaci&#243;n total de personas con edad igual o superior a 60 a&#241;os, de conformidad con los datos actualmente disponibles en el portal de IBGE (Instituto Brasile&#241;o de Geograf&#237;a Estad&#237;stica), con una expectativa de vida al nacer que alcaza un promedio de 72,05 a&#241;os<sup>2</sup>. Por otro lado, la expectativa de vida de los que llegan a los 60 a&#241;os crece de forma expresiva, cambiando el perfil epidemiol&#243;gico, con gran prevalencia de las enfermedades cardiovasculares en esa poblaci&#243;n<sup>3</sup>. </p>
      <p>Los datos epidemiol&#243;gicos revelan que la mortalidad por enfermedades cardiovasculares (ECV) aumenta con el avance de la edad. Esos n&#250;meros expresan la importancia del proceso de la aterosclerosis en el adulto mayor, que vuelve fundamental su prevenci&#243;n y detecci&#243;n. Sin embargo, estudios a&#250;n incipientes en el campo de la geriatr&#237;a son controvertidos con respecto al valor predictivo de los factores de riesgo (FR) para ECV en el adulto mayor, principalmente tras los 75 a&#241;os. </p>
      <p>En las &#250;ltimas cuatro d&#233;cadas, los FR principalmente para las ECV vienen siendo exhaustivamente estudiados<sup>4-7</sup>. El envejecimiento, la hipertensi&#243;n arterial (HA), la dislipidemia, el diabetes melito II (DM II), el humo, el sedentarismo y la obesidad, por ejemplo, est&#225;n entre los FR capaces de conllevar la disfunci&#243;n endotelial y, consecuentemente, las alteraciones vasculares con clara asociaci&#243;n entre esos factores de riesgo y la aterosclerosis<sup>6</sup>. </p>
      <p>La presencia de lesiones ateroscler&#243;ticas est&#225; asociada, entre otros FR, al LDL colesterol (LDL-c) <underline>&gt;</underline> 100 mg/dL (2,6 mmol/L) y HDL colesterol (HDL-c) &lt; 40 mg/dL (1,04 mmol/L)<sup>8,9</sup>, mientras que, por otro lado, el HDL-c en un nivel elevado viene siendo reconocida como antiaterog&#233;nica. Ese rol del HDL-c, a pesar de que no est&#233; totalmente establecido, se atribuye a su capacidad de mediaci&#243;n del transporte reverso del colesterol. </p>
      <p>Otros mecanismos protectores del HDL-c vienen siendo propuestos, como la inhibici&#243;n de la oxidaci&#243;n del LDL-c, reducci&#243;n de la viscosidad sangu&#237;nea, regulaci&#243;n de la s&#237;ntesis de prostaglandinas y tromboxano y activaci&#243;n de la fibrin&#243;lisis, acci&#243;n sobre la funci&#243;n endotelial y acci&#243;n antiinflamat&#243;ria<sup>10-12</sup>.</p>
      <p>En el estudio EPESE<sup>13</sup>, se sugiri&#243; que en la poblaci&#243;n adulta mayor el nivel de HDL-c es un predictor m&#225;s espec&#237;fico y poderoso de riesgo de muerte por enfermedad arterial coronaria (EAC) que el colesterol total. Corti et al.<sup>14</sup>, a partir de datos del EPESE, concluyeron que valores anormales de colesterol estaban relacionados a la muerte por EAC en adultos mayores. As&#237;, la exclusi&#243;n de los trabajos que analizan la relaci&#243;n del colesterol con ECV se hizo inapropiada. En el <italic>The Northern Manhattan Study</italic><sup>15</sup> los autores infirieron que el HDL-c elevado est&#225; asociado a riesgos reducidos de accidente vascular encef&#225;lico (AVE) isqu&#233;mico en el adulto mayor, considerando el HDL-c un importante y modificable FR para AVE. Otro estudio relacion&#243; el HDL-c bajo con el riesgo de mortalidad por EAC y AVE en adultos mayores<sup>16</sup>. Por otro lado, en el estudio PROSPER<sup>17</sup> no fue altamente significativa la reducci&#243;n de eventos vasculares, debiendo existir cautela en el an&#225;lisis de esos datos hasta que otros estudios confirmen esos beneficios. No obstante, el estudio HPS<sup>18</sup> encontr&#243; reducci&#243;n de eventos vasculares mayores en pacientes con niveles elevados de HDL-c tratados con sinvastatina, cuando comparados con placebo. </p>
      <p>De esa forma, este estudio tuvo como objetivo evaluar las variables cl&#237;nicas y laboratoriales y la ocurrencia de eventos CV fatales y no fatales, como: enfermedad arterial coronaria (angina, infarto agudo del miocardio y revascularizaci&#243;n mioc&#225;rdica percut&#225;nea o quir&#250;rgica); accidente vascular encef&#225;lico; accidente isqu&#233;mico transitorio (TIA); enfermedad de car&#243;tida; e insuficiencia cardiaca (IC), en adultos mayores estratificados de conformidad con el comportamiento del HDL-c en seguimiento de 8 a&#241;os. </p>
      <p>
        <bold>M&#233;todo</bold>
      </p>
      <p>Para el presente estudio, se evaluaron a 81 individuos seguidos por 96,68 &#177; 11,57 meses, en el ambulatorio del Hospital Universitario Pedro Ernesto, divididos en tres grupos, constituidos por el comportamiento de HDL-c determinado en la evaluaci&#243;n inicial (evaluaci&#243;n 1) y en la segunda evaluaci&#243;n (evaluaci&#243;n 2), a saber:</p>
      <p>1) Grupo normal (GN), constituido por individuos con valores de HDL-c normal, compuesto por 31 individuos, con 10 de ellos del sexo masculino (32,3%) y 21 del sexo femenino (67,7%).</p>
      <p>2) Grupo bajo (GB), con valores de HDL-c anormales (bajo), compuesto por 21 individuos, con 6 de ellos del sexo masculino (28,6%) y 15 del sexo femenino (71,4%).</p>
      <p>3) Grupo variable (GV), con valores de HDL-c variables en las dos evaluaciones, conformado por 29 individuos, con 15 de ellos del sexo masculino (51,7%) y 14 del sexo femenino (48,3%). </p>
      <p>Para la conformaci&#243;n de los grupos, se tuvieron en cuenta los valores del HDL-c seg&#250;n las recomendaciones de la IV Directriz Brasile&#241;a sobre Dislipidemia y Prevenci&#243;n de la Aterosclerosis<sup>19</sup>. Se consideraron como valores normales aquellos iguales o superiores a 40 mg/dL para el sexo masculino e iguales o superiores a 50 mg/dL para el sexo femenino. Los valores inferiores a esos puntos de corte se consideraron bajos, correspondiendo a valores anormales.</p>
      <p>Los pacientes que acordaron con participar en el estudio pasaron por entrevista y se sometieron a examen cl&#237;nico y laboratorial. De la evaluaci&#243;n 1, cerca de 8 a&#241;os antes, se obtuvieron datos demogr&#225;ficos y epidemiol&#243;gicos, adem&#225;s de las condiciones m&#233;dicas previas y de los medicamentos en uso. Para la evaluaci&#243;n 2, se obtuvieron los mismos datos, y se enfatiz&#243; la identificaci&#243;n de eventos CV fatales y no fatales, tales como: EAC (angina, infarto agudo de miocardio y revascularizaci&#243;n mioc&#225;rdica percut&#225;nea o quir&#250;rgica); AVE y TIA; enfermedad de car&#243;tida; demencia; e IC. En los casos de &#243;bito, la causa se apur&#243; con an&#225;lisis de la documentaci&#243;n m&#233;dica existente. </p>
      <p>La evaluaci&#243;n laboratorial incluy&#243; la obtenci&#243;n de los valores de colesterol total (CT), de los triglic&#233;ridos (TG), y del HDL-c y el LDL-c. Se consideraron normales los valores CT&lt; 200 mg/dL, LDL-c &lt; 130 mg/dL, y triglic&#233;ridos &lt; 150 mg/dL.</p>
      <p>Para la caracterizaci&#243;n de cintigraf&#237;a arterial quir&#250;rgica se tuvo en cuenta la revascularizaci&#243;n mioc&#225;rdica percut&#225;nea o coronaria, la enfermedad mioc&#225;rdica positiva<sup>20 </sup>y la ecocardiograma con alteraciones de contractilidad bien definidas para coronariopatia<sup>21</sup>. Para la caracterizaci&#243;n de evento vascular cerebral, se tuvo en cuenta la tomograf&#237;a computarizada cerebral o la resonancia magn&#233;tica con alteraciones bien definidas para lesi&#243;n cerebral y o d&#233;ficit motor, as&#237; como para TIA, evento de p&#233;rdida de conciencia o d&#233;ficit motor transitorio bien documentado por atenci&#243;n hospitalaria. La enfermedad vascular cerebral asociada a dos d&#233;ficits cognitivos, siendo uno de ellos la memoria, se la consider&#243; como demencia seg&#250;n el Manual Diagn&#243;stico y Estad&#237;stico de Trastornos Mentales, 4&#170; edici&#243;n<fn id="tx01-body2"><label><sup>*</sup></label><p>. Se tuvo en cuenta la enfermedad carot&#237;dea cuando a la ecocardiograf&#237;a Doppler se evidenciara la presencia de placas ateroscler&#243;ticas. Cualesquiera otras intercurrencias, como c&#225;ncer, hipotiroidismo, etc., se las consideraron como otros eventos.</p></fn></p>
      <p>Se tom&#243; la presi&#243;n arterial (PA) en reposo dos veces durante la consulta, con intervalo de cinco minutos como m&#237;nimo, con el paciente en la posici&#243;n sentada, teniendo el promedio de esas lecturas como el valor adoptado. La medici&#243;n de la PA y su clasificaci&#243;n se realizaron seg&#250;n los criterios del V DBHA<sup>22</sup>. </p>
      <p>El an&#225;lisis estad&#237;stico se llev&#243; a cabo con la utilizaci&#243;n del programa "SPSS for Windows", versi&#243;n 8.0.0. La prueba de regresi&#243;n log&#237;stica se utiliz&#243; para evaluar la probabilidad de ocurrencia o no de un evento. </p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Con relaci&#243;n a la edad y al tiempo de seguimiento, la comparaci&#243;n entre los promedios de los tres grupos no present&#243; significado estad&#237;stico, as&#237; como la distribuci&#243;n por sexo (<xref ref-type="table" rid="tab01-body2">Tabla 1</xref>).</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt01-es.jpg"/></table-wrap>
      <p>La comparaci&#243;n de las variables antropom&#233;tricas, metab&#243;licas y de presi&#243;n de las evaluaciones 1 y 2 se encuentra descrita en las <xref ref-type="table" rid="tab02-body2">Tablas 2</xref> y <xref ref-type="table" rid="tab03-body2">3</xref>, respectivamente. Como se puede observar, en ambas evaluaciones, solamente se hall&#243; diferencia significativa en la comparaci&#243;n de los promedios de HDL-c y de TG, donde el grupo B present&#243; promedios menores de HDL-c y valores mayores de TG cuando comparados a los dem&#225;s grupos. </p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt02-es.jpg"/></table-wrap>
      <table-wrap id="tab03-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt03-es.jpg"/></table-wrap>
      <p>La comparaci&#243;n de los promedios de la presi&#243;n arterial sist&#243;lica (PAS) y de la presi&#243;n arterial diast&#243;lica (PAD), en las dos evaluaciones (<xref ref-type="table" rid="tab02-body2">Tablas 2</xref> y <xref ref-type="table" rid="tab03-body2">3</xref>), no revel&#243; diferencia estad&#237;stica significativa entre los tres grupos, as&#237; como la prevalencia de hipertensi&#243;n arterial.</p>
      <p>
        <bold>An&#225;lisis de los Eventos con Relaci&#243;n al HDL-c</bold>
      </p>
      <p>La <xref ref-type="table" rid="tab04-body2">Tabla 4</xref> revela la distribuci&#243;n de eventos en los tres grupos con relaci&#243;n al comportamiento del HDL-c. </p>
      <table-wrap id="tab04-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt04-es.jpg"/></table-wrap>
      <p>El grupo con HDL-c bajo en las dos evaluaciones present&#243; porcentaje significativamente mayor de eventos CV que los otros dos grupos. Ocurrieron 13 eventos CV en el grupo normal (41,9%); 16 (76,2%) en el grupo bajo; y 12 (41,4%) en el grupo variable (&#967;<sup>2</sup>=7, 419; p=0,024). </p>
      <p>La <xref ref-type="table" rid="tab05-body2">Tabla 5</xref> detalla la distribuci&#243;n por tipos de eventos, demostrando que no hubo diferencia entre los grupos en cuanto al tipo de evento CV ocurrido. </p>
      <table-wrap id="tab05-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt05-es.jpg"/></table-wrap>
      <p>La ocurrencia de eventos en un modelo de regresi&#243;n log&#237;stica se consider&#243; como variable dependiente, y la edad, la PAS, la PAD, el colesterol, el HDL-c y los triglic&#233;ridos obtenidos en la primera evaluaci&#243;n, como variables independientes. En ese modelo, solamente la edad y el HDL-c mantuvieron correlaci&#243;n significativa con la ocurrencia de eventos CV. Se observ&#243; que cuanto mayor la edad, mayor la ocurrencia de eventos cardiovasculares (<italic>odds ratio</italic> = 1,187, p = 0,0230) y cuanto menor el HDL-c, mayor la ocurrencia de eventos cardiovasculares (<italic>odds ratio</italic> = 0,9375, p = 0,0102) (<xref ref-type="table" rid="tab06-body2">Tabla 6</xref>).</p>
      <table-wrap id="tab06-body2">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt06-es.jpg"/></table-wrap>
      <p>El an&#225;lisis de la distribuci&#243;n de las muertes no revel&#243; diferencia con valor estad&#237;stico significativo (&#967;<sup>2</sup>=1,359, p=0,507). </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Junto con una mayor expectativa de vida al nacer, la incapacidad cr&#243;nica y la institucionalizaci&#243;n vienen evidenciando mayor prevalencia en los adultos mayores, con predominancia en el sexo femenino<sup>1</sup>. Como consecuencia del aumento de la prevalencia de las enfermedad cr&#243;nicas y degenerativas y sus secuelas, la dependencia funcional representar&#225; un reto adicional<sup>2</sup>. En 2005, el gasto <italic>per capita</italic> de la red hospitalaria del Sistema &#218;nico de Salud (SUS) con varones de 60 a 69 a&#241;os fue m&#225;s que cuatro veces superior al gasto con varones de 30 a 39 a&#241;os, sin embargo solamente la mitad del valor del grupo con 80 a&#241;os o m&#225;s<sup>23</sup>.</p>
      <p>La magnitud de los cambios demogr&#225;ficos y epidemiol&#243;gicos exige la urgente adopci&#243;n de una pol&#237;tica asistencial al adulto mayor<sup>23</sup>. La expectativa de salud es m&#225;s importante que la expectativa de vida misma, constituyendo un reto levantado por la Organizaci&#243;n mundial de Salud: "&#191;C&#243;mo prevenir y postergar la enfermedad y la incapacidad, manteniendo la salud, la independencia y la movilidad de la poblaci&#243;n que envejece?"<sup>1</sup>.</p>
      <p>La ECV es la principal causa de muerte y de incapacidad en las personas con edad superior a los 65 a&#241;os, pese al progresivo descenso de las ECV en la poblaci&#243;n desde la d&#233;cada de 70. Las medidas preventivas para las ECV, consecuentemente, adquieren especial destaque<sup>1,24</sup>. LA ECV tiene un importante impacto sobre la expectativa de vida, adem&#225;s de contribuir al empeoramiento de la calidad de vida, conllevando la p&#233;rdida de la independencia y la institucionalizaci&#243;n.</p>
      <p>Numerosos estudios vienen abordando la influencia de los FR en la g&#233;nesis de la aterosclerosis<sup>25-28</sup>, sin embargo, la literatura presenta resultados controvertidos con relaci&#243;n al valor predictivo de algunos factores de riesgo para ECV en los adultos mayores, principalmente tras los 75 a&#241;os<sup>29,30</sup>. El surgimiento de estudios sobre los factores de riesgo para la aterosclerosis, con dise&#241;o adecuado al adulto mayor, han salido a relucir nuevos hechos<sup>30</sup> en la literatura, aunque los resultados todav&#237;a no presentan algunas discordancias entre si.</p>
      <p>Diversos trabajos han considerado el envejecimiento como uno de los m&#225;s importantes FR independiente para la morbilidad y la mortalidad por ECV, con el endotelio vascular como un evidente &#243;rgano blanco<sup>25,28,31</sup>. Luscher y Barton<sup>31</sup> estudiaron la influencia de la edad, de la HA y de los l&#237;pidos sobre el endotelio vascular, y observaron que todas las tres condiciones se hallaban relacionadas a las alteraciones funcionales del endotelio, y pod&#237;an contribuir a la proliferaci&#243;n vascular, la trombosis, al vasoespasmo y la isquemia. Dentro del marco de los factores de riesgo, este estudio se proyect&#243; para que se estableciera la importancia del HDL-c para la ocurrencia de la ECV en el adulto mayor.</p>
      <p>Inicialmente, se realiz&#243; la comparaci&#243;n de las variables epidemiol&#243;gicas entre los tres grupos. La evaluaci&#243;n de los promedios para la edad, el sexo y el tiempo de seguimiento revel&#243; la homogeneidad entre los tres grupos sin diferencia estad&#237;stica significativa y, de esa forma, no tuvieron influencia en el an&#225;lisis de los eventos.</p>
      <p>Los &#237;ndices antropom&#233;tricos utilizados fueron: el peso, la altura y el &#237;ndice de masa corp&#243;rea (IMC), utilizado por guardar una buena correlaci&#243;n con la medida directa de la grasa corporal. En el presente estudio, no hubo diferencias entre los grupos en cuanto los promedios de las variables antropom&#233;tricas analizadas, lo que est&#225; de acuerdo con el estudio de Price, donde el IMC no se asoci&#243; positivamente a la mortalidad circulatoria en varones y en mujeres<sup>32</sup>. </p>
      <p>Los promedios de la PAS y de la PAD no mostraron diferencias estad&#237;sticas entre los tres grupos en ambas las evaluaciones, no interfiriendo con los resultados. Un an&#225;lisis reciente del <italic>Framingham Heart Study</italic> revel&#243; que la acumulaci&#243;n de FR, entre ellos la HA, contribuye a la menor sobrevida y la mayor incapacidad en adultos mayores<sup>33</sup>. Los efectos de la HA sobre la morbimortalidad CV se hallan bien establecidos<sup>34</sup>. En este estudio, la PA, evaluada en modelo de regresi&#243;n log&#237;stica, no revel&#243; relaci&#243;n estad&#237;sticamente significativa con la ocurrencia de eventos cardiovasculares. </p>
      <p>Se determinaron las variables metab&#243;licas en la fase inicial del trabajo, en la evaluaci&#243;n 1, y se las evaluaron nuevamente por lo menos cinco a&#241;os despu&#233;s, en la evaluaci&#243;n 2, correlacion&#225;ndolas a los eventos encontrados. </p>
      <p>Los niveles elevados de colesterol total y de LDL-c se vienen mostrando como importantes factores de riesgo para la incidencia y mortalidad total por ECV en individuos de mediana edad en diversos estudios prospectivos, incluyendo el <italic>Honolulu Heart Program</italic> (HHP)<sup>18</sup>, sin embargo, esos hallazgos en los adultos mayores vienen siendo menos consistentes. En el HHP, la proporci&#243;n de reducci&#243;n en la tasa de eventos fue similar en j&#243;venes y en adultos mayores con edad superior a 70 a&#241;os. En los resultados obtenidos en el presente estudio, no hubo relaci&#243;n entre ECV colesterol total y LDL-c en adultos mayores.</p>
      <p> El an&#225;lisis de los promedios encontrados para el colesterol en la evaluaci&#243;n 1 revel&#243; valores m&#225;s altos con relaci&#243;n a los valores obtenidos en la evaluaci&#243;n 2 en todos los grupos, por tanto, valores menores se obtuvieron en los individuos con m&#225;s edad. Esa observaci&#243;n se halla de acuerdo con la literatura actual, que refiere baja en la prevalencia de perfil lip&#237;dico anormal con el avance de la idade<sup>24</sup>. Por otro lado, la utilizaci&#243;n de medicamentos espec&#237;ficos para el tratamiento de dislipidemia podr&#237;a tambi&#233;n contribuir a un cambio observado. Adem&#225;s de eso, algunos estudios epidemiol&#243;gicos sugieren que la relaci&#243;n entre la EAC y los niveles de colesterol sufren descenso seg&#250;n el avance de la edad, llevando a creer as&#237; que habr&#237;a un menor beneficio en el tratamiento del colesterol en los adultos mayores<sup>24,35,36</sup>. Sin embargo, algunos estudios evidencian resultados positivos en lo que dice respecto al tratamiento, como ocurri&#243; en el <italic>Heart Protection Study</italic><sup>18</sup>, d&#243;nde hab&#237;a un subgrupo de pacientes con edad superior a 70 a&#241;os, cuya mayor&#237;a no excedi&#243; los 75 a&#241;os, habiendo una reducci&#243;n en el riesgo vascular. </p>
      <p>Despu&#233;s de la utilizaci&#243;n de un modelo de regresi&#243;n log&#237;stica donde se consider&#243; la ocurrencia de eventos como variable dependiente, y edad, PAS, PAD, CT, HDL-c y TG como variables independientes en la evaluaci&#243;n 1, el colesterol no se hall&#243; asociado significativamente para el desarrollo de eventos cardiovasculares. </p>
      <p>Los promedios de los triglic&#233;ridos fueron significativamente diferentes en las dos evaluaciones. En este estudio, los niveles m&#225;s elevados de triglic&#233;ridos ocurrieron en el grupo con HDL-c m&#225;s bajo, tanto en la evaluaci&#243;n 1 como en la evaluaci&#243;n 2, de acuerdo con la estrecha relaci&#243;n entre el transporte reverso de colesterol, el HDL-c y los triglic&#233;ridos<sup>37,38</sup>. No obstante, en un modelo de regresi&#243;n log&#237;stica, la variable triglic&#233;ridos no present&#243; relaci&#243;n significativa con la ECV. Aunque an&#225;lisis univariados de estudios epidemiol&#243;gicos demuestran que la hipertrigliceridemia est&#225; asociada con un aumento de EAC en varones y mujeres, an&#225;lisis multivariados vienen mostrando resultados conflictivos para la caracterizaci&#243;n de los triglic&#233;ridos como factor independiente de riesgo para EAC, pareciendo ser un factor m&#225;s importante para nuevos eventos en la mujer que en los varones<sup>8</sup>. </p>
      <p>El modelo de regresi&#243;n log&#237;stica revel&#243; que cuanto mayor la edad mayor la ocurrencia de eventos CV (<italic>odds ratio</italic> = 1,187, p = 0,0230), seg&#250;n la literatura que refiere la relaci&#243;n directa entre mortalidad CV y edad<sup>38</sup>. </p>
      <p> El comportamiento del HDL-c revel&#243; expresi&#243;n estad&#237;stica para ocurrencia de eventos (&#967;<sup>2</sup>=7,419, p=0,024). En el an&#225;lisis del modelo de regresi&#243;n log&#237;stica, esa relaci&#243;n se mantuvo, mostrando que cuanto mayor el HDL-c menor la ocurrencia de eventos CV. </p>
      <p>El HDL-c viene siendo identificado como factor de riesgo mayor e independiente, con relaci&#243;n m&#225;s importante para el desarrollo de EAC que el colesterol total y el LDL-c<sup>39</sup>. Otro aspecto que viene siendo evidenciado es el valor predictivo para EAC del HDL-c bajo, mayor en la mujer que en el var&#243;n<sup>38</sup>.</p>
      <p>Se intenta explicar los efectos antiaterog&#233;nicos del HDL-c por sus propiedades antiinflamatorias, antioxidantes, antiagregantes, anticoagulantes y profibrinol&#237;ticas, que promueven el mantenimiento de las funciones endoteliales. As&#237;, los niveles bajos de HDL-c contribuyeron al aumento de la ECV por la p&#233;rdida de los efectos antiaterog&#233;nicos, debido al menor transporte reverso del colesterol, menor acci&#243;n antiinflamatoria y p&#233;rdida de las propiedades antitromb&#243;ticas.</p>
      <p>Frecuentemente, se observan bajos niveles de HDL-c en pacientes con EAC, mientras que s&#237;ndromes gen&#233;ticas que cursan, con frecuencia, con HDL-c elevado est&#225;n asociadas a las reducciones de ocurrencia de EAC y la mayor longevidad<sup>40</sup>. El inter&#233;s sobre el HDL-c se hizo m&#225;s fuerte por &#233;ste hallarse frecuentemente en asociaci&#243;n con niveles elevados de lipoprote&#237;nas aterog&#233;nicas, inclusive el VLDL y el LDL-c de clase peque&#241;as y densas, y tambi&#233;n con el s&#237;ndrome metab&#243;lico, implicando resistencia a la insulina, intolerancia a la glucosa y hipertensi&#243;n arterial<sup>40</sup>. La complejidad del metabolismo de los HDL-c necesita a&#250;n de otros estudios.</p>
      <p>La ocurrencia elevada de eventos en los tres grupos podr&#237;a estar relacionada a la relaci&#243;n directa de eventos y de mortalidad con la edad y con el tiempo de exposici&#243;n a los FR<sup>33</sup>, de forma que en el grupo de HDL-c bajo, solamente el 23,8% no presentaron evento alguno. Sin embargo, no hubo predominio de ning&#250;n tipo espec&#237;fico de evento CV relacionado al comportamiento del HDL-c.</p>
      <p>Se resalta que este estudio tiene el car&#225;cter de observaci&#243;n longitudinal, con tiempo prolongado de seguimiento &#150;ocho a&#241;os&#150; y tiene como principal aporte la demostraci&#243;n de la correlaci&#243;n significativa del HDL-c persistentemente bajo con la ocurrencia de eventos CV.</p>
      <p>Este estudio presenta limitaciones resultantes del n&#250;mero relativamente peque&#241;o de pacientes seguidos y no se aconseja que se haga generalizaci&#243;n de sus resultados, pese a sus importantes hallazgos. Los desenlaces evaluados no son todos considerados de gran importancia, sin embargo, pueden caracterizar de forma muy aceptable la presencia de enfermedad ateroscler&#243;tica significativa y la ocurrencia de eventos cardiovasculares en una muestra de adultos mayores seguida prospectivamente. Adem&#225;s de ello, esas condiciones presentan gran repercusi&#243;n sobre la calidad de vida, que se constituy&#243; en uno de los principales objetivos del abordaje de poblaciones de este grupo de edad. </p>
      <p>En conclusi&#243;n, la ocurrencia de valores de HDL-c permanentemente bajos en adultos mayores, a lo largo de 8 a&#241;os de seguimiento, estaba asociado a mayores niveles de triglic&#233;ridos en las dos evaluaciones, pero no se relacion&#243; a la presi&#243;n arterial, los &#237;ndices antropom&#233;tricos y el LDL-c. La edad y la presencia de HDL-c con dosificaciones permanentemente bajas fueron factores de riesgo para el desarrollo de eventos cardiovasculares, mientras que el colesterol total y la presi&#243;n arterial no revelaron relaci&#243;n significativa. Los datos de este estudio enfatizan la necesidad de evaluaci&#243;n del perfil lip&#237;dico tambi&#233;n en adultos mayores, para identificar pacientes con mayor riesgo potencial para enfermedad CV.</p>
      <p>
        <bold>Agradecimientos</bold>
      </p>
      <p>Los autores le agradecen a Simone Offrede, bi&#243;loga del Hospital Universitario Pedro Ernesto, responsable de la extracci&#243;n de las muestras sangu&#237;neas, as&#237; como del control de llamada de los pacientes.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Elizabete Viana de Freitas, por el Hospital Universitario Pedro Ernesto, de la Universidad del R&#237;o de Janeiro.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Importance of HDL-c for the occurrence of cardiovascular disease in the elderly</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Studies on the impact of HDL-c and the occurrence of cardiovascular disease (CV) in the elderly are scarce. OBJECTIVE: To evaluate the clinical and laboratory variables and the occurrence of CV events in elderly patients stratified according to the behavior of HDL-c during an eight-year follow up. METHODS: We evaluated 81 elderly patients, mean age of 68.51 &#177; 6.32 years (38.2% male), in two stages (A1 and A2), with a minimum interval of five years. The subjects were divided into 3 groups according to HDL-c levels: normal HDL-c in both assessments (NG) (n = 31), low HDL-c in both assessments (LG) (n = 21) and variable HDL-c in A1 and A2 (VG) (n = 29). Main CV events were recorded: coronary heart disease (angina, myocardial infarction, percutaneous / surgical myocardial revascularization), stroke, transient ischemic attack, carotid disease, dementia and heart failure. RESULTS: The groups did not differ in gender and age in A1 and A2. Mean triglyceride levels were lower in the NG in A1 (p = 0.027) and A2 (p = 0.016) than in the LG. The distribution of CV events was as follows: 13 events in the NG (41.9%), 16 (76.2%) in the LG, and 12 (41.4%) in the VG (&#967;2 = 7.149, p = 0.024). The logistic regression analysis showed that the older the patient (OR = 1.187, p = 0.0230) and the lower the HDL-c (OR = 0.9372, p = 0.0102), the greater the occurrence of events CV. CONCLUSION: Permanently low HDL-c during eight years of monitoring is a risk factor for the development of CV events in the elderly.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Cholesterol HDL</kwd>
        <kwd>Cardiovascular Diseases</kwd>
        <kwd>Aging</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p><undefined id="tx-body3"/>Importance of HDL-c for the occurrence of cardiovascular disease in the elderly </p>
      <p>
        <bold>Elizabete Viana de Freitas; Andr&#233;a Ara&#250;jo Brand&#227;o; Roberto Pozzan; Maria Eliane Magalh&#227;es; Fl&#225;via Fonseca; Oswaldo Pizzi; &#201;rika Campana; Ayrton Pires Brand&#227;o</bold>
      </p>
      <p>Hospital Universit&#225;rio Pedro Ernesto, UERJ, Rio de Janeiro, RJ, Brasil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Studies on the impact of HDL-c and the occurrence of cardiovascular disease (CV) in the elderly are scarce.</p>
      <p><bold>OBJECTIVE:</bold> To evaluate the clinical and laboratory variables and the occurrence of CV events in elderly patients stratified according to the behavior of HDL-c during an eight-year follow up.</p>
      <p><bold>METHODS:</bold> We evaluated 81 elderly patients, mean age of 68.51 &#177; 6.32 years (38.2% male), in two stages (A1 and A2), with a minimum interval of five years. The subjects were divided into 3 groups according to HDL-c levels: normal HDL-c in both assessments (NG) (n = 31), low HDL-c in both assessments (LG) (n = 21) and variable HDL-c in A1 and A2 (VG) (n = 29). Main CV events were recorded: coronary heart disease (angina, myocardial infarction, percutaneous / surgical myocardial revascularization), stroke, transient ischemic attack, carotid disease, dementia and heart failure.</p>
      <p><bold>RESULTS:</bold> The groups did not differ in gender and age in A1 and A2. Mean triglyceride levels were lower in the NG in A1 (p = 0.027) and A2 (p = 0.016) than in the LG. The distribution of CV events was as follows: 13 events in the NG (41.9%), 16 (76.2%) in the LG, and 12 (41.4%) in the VG (&#967;<sup>2</sup> = 7.149, p = 0.024). The logistic regression analysis showed that the older the patient (OR = 1.187, p = 0.0230) and the lower the HDL-c (OR = 0.9372, p = 0.0102), the greater the occurrence of events CV.</p>
      <p><bold>CONCLUSION:</bold> Permanently low HDL-c during eight years of monitoring is a risk factor for the development of CV events in the elderly.</p>
      <p><bold>Key words:</bold> Cholesterol HDL; Cardiovascular Diseases; Aging.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Worldwide, the number of people aged 60 years or over has grown rapidly<sup>1</sup>. 10.5% of the total population of Brazil are aged 60 years or over, according to data currently available on the IBGE website, and life expectancy at birth reached an average of 72.05 years<sup>2</sup>. Furthermore, life expectancy for those reaching 60 years of age increased significantly, changing the epidemiological profile, with a high prevalence of cardiovascular diseases in this population<sup>3</sup>. </p>
      <p>Epidemiological data show that mortality from cardiovascular diseases (CVD) increases with age. These numbers reflect the importance of the atherosclerotic process in the elderly, and this makes its prevention and detection essential. However, studies in the field of geriatrics are still incipient and controversial as to the predictive value of risk factors (RF) for CVD in the elderly, especially after the age of 75 years. </p>
      <p>Especially in the last four decades, RF for CVD were extensively studied<sup>4-7</sup>. Aging, high blood pressure (HBP), dyslipidemia, type II diabetes mellitus (DM II), smoking habit, obesity and a sedentary lifestyle, for example, are some of the RF that can lead to endothelial dysfunction and, therefore, to vascular changes; also there is a clear association between these risk factors and atherosclerosis<sup>6</sup>.</p>
      <p>The presence of atherosclerotic lesions is associated, among other RF, with LDL cholesterol (LDL-c) <underline>&gt;</underline> 100 mg / dL (2.6 mmol / L) and HDL cholesterol (HDL-c) &lt; 40 mg / dL (1.04 mmol / L)<sup>8,9</sup>. On the other hand, high levels of HDL-c have been recognized as having antiatherogenic effects. The role of HDL-c, though not yet fully established, is attributed to its ability to mediate reverse cholesterol transport. </p>
      <p>Other protective HDL-c mechanisms have been proposed, such as inhibition of LDL-c oxidation, reduction in blood viscosity, regulation of prostaglandins and thromboxane synthesis and activation of fibrinolysis, influence on endothelial function and anti-inflammatory action<sup>10-12</sup>. </p>
      <p>The EPESE<sup>13</sup> study suggested that, in the elderly population, HDL-c levels are a more specific and powerful predictor of risk of death from coronary artery disease (CAD) than total cholesterol. Corti et al<sup>14</sup> concluded from the EPESE data that abnormal cholesterol levels are associated with CVD death in the elderly, and that their exclusion from studies that evaluate the relationship between cholesterol and CVD is improper. In "The Northern Manhattan Study"<sup>15</sup>, the authors infer that high HDL-c is associated with a reduced risk of ischemic stroke in the elderly, and they considered HDL-c as an important modifiable RF for stroke. Another study showed an association between low HDL-C and mortality risk from CVD and stroke in the elderly<sup>16</sup>. On the other hand, in the PROSPER study<sup>17</sup>, there was no highly significant reduction in vascular events, and there should be caution in the analysis of these data until other studies confirm these benefits. However, the HPS<sup>18</sup> study found a greater reduction in vascular events in patients with high levels of HDL-c treated with simvastatin when compared to those treated with placebo. </p>
      <p>Therefore, the objective of this study was to evaluate clinical and laboratory variables and the occurrence of fatal and non fatal CV events, such as coronary artery disease (angina, myocardial infarction and percutaneous or surgical myocardial revascularization), stroke, transient ischemic attack (TIA), carotid artery disease, and heart failure (HF), in elderly patients stratified according to the behavior of the HDL-c during an eight-year follow up.</p>
      <p>
        <bold>Method</bold>
      </p>
      <p>In this study, 81 individuals were followed up during 96.68 &#177; 11.57 months in the outpatient clinic of Hospital Universit&#225;rio Pedro Ernesto, and they were divided into three groups, which were formed according to HDL-c behavior, which was determined at the initial assessment (assessment 1) and at the second assessment (assessment 2), namely: </p>
      <p>1. Normal group (NG), consisting of individuals with normal values of HDL-c, composed of 31 individuals, 10 males (32.3%) and 21 females (67.7%). </p>
      <p>2. Low group (LG) with abnormal values of HDL-c (low), consisting of 21 individuals, 6 males (28.6%) and 15 females (71.4%) </p>
      <p>3. Variable group (VG), with variable values of HDL-c at the two assessments, composed of 29 individuals, 15 males (51.7%) and 14 females (48.3%). </p>
      <p>To form the groups, we considered the values of HDL-c in accordance with the recommendations of the IV Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis<sup>19</sup>, and HDL-c values greater than or equal to 40 mg / dL for males, and greater than or equal to 50 mg / dL for females were considered normal. The values below these cut-off points were considered low, corresponding to abnormal values. </p>
      <p>Patients who agreed to participate were interviewed and underwent clinical examination and laboratory tests. From assessment 1, conducted about eight years in the past, we obtained demographic and epidemiological data, in addition to past medical conditions and medication in use. From assessment 2, the same data were obtained, with emphasis on the identification of fatal and non-fatal CV events, such as CAD (angina, myocardial infarction and percutaneous or surgical myocardial revascularization), stroke and TIA, carotid disease, dementia, and HF. In cases of death, the cause was established by analysis of the existing medical documentation. </p>
      <p>The laboratory evaluation included obtaining the values of total cholesterol (TC), triglycerides (TG), HDL-c, and LDL-c. The following values were considered normal: TC &lt;200 mg/dL, LDL-c &lt;130 mg/dL, and triglycerides &lt;150 mg/dL. </p>
      <p>For coronary artery disease characterization, surgical or percutaneous myocardial revascularization, positive myocardial scintigraphy and echocardiography<sup>20</sup> with well-defined contractility changes for coronary disease were taken into account<sup>21</sup>. For cerebrovascular event characterization, brain computed tomography or magnetic resonance imaging with well-defined changes for brain injury and/or motor deficit were taken into account. For TIA, an event of temporary loss of consciousness or motor deficit that was well documented by the hospital was taken into account. A cerebrovascular disease associated with two cognitive deficits, one of them involving memory, was considered as dementia according to the <italic>Diagnostic and Statistical Manual of Mental Disorders, 4th edition</italic>. Carotid disease was considered characterized when the echo-Doppler showed the presence of atherosclerotic plaques. Any other complications, such as cancer, hypothyroidism, etc., were considered as events. </p>
      <p>Resting blood pressure (BP) was measured twice during the consultation, with an interval of at least five minutes, with the patient in a sitting position, and the mean value of the readings was recorded. BP measurement and its classification were performed according to V Brazilian Guidelines of Arterial Hypertension criteria<sup>22</sup>. </p>
      <p>Statistical analysis was performed using the program SPSS for Windows, version 8.0.0. The test of logistic regression was used to assess the probability of occurrence of an event. </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>In reference to age and time of monitoring, the comparison of the mean values of the three groups showed no statistical significance, and the same was observed in reference to the distribution by gender (<xref ref-type="table" rid="tab01-body3">table 1</xref>). </p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt01-en.jpg"/></table-wrap>
      <p>The comparisons of anthropometric, metabolic and pressure variables of assessments 1 and 2 are described in <xref ref-type="table" rid="tab02-body3">tables 2</xref> and <xref ref-type="table" rid="tab03-body3">3</xref>, respectively. The only significant difference observed in both assessments was in the comparison of mean HDL-c and TG levels, in which group B had lower HDL-c levels and higher TG levels, when compared to other groups. </p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt02-en.jpg"/></table-wrap>
      <table-wrap id="tab03-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt03-en.jpg"/></table-wrap>
      <p>The comparison of mean systolic blood pressure (SBP) values and mean diastolic blood pressure (DBP) values, in both assessments (<xref ref-type="table" rid="tab02-body3">tables 2</xref> and <xref ref-type="table" rid="tab03-body3">3</xref>), showed no statistical difference among the three groups and the prevalence of high blood pressure. </p>
      <p>Analysis of events in reference to HDL-c levels</p>
      <p><xref ref-type="table" rid="tab04-body3">Table 4</xref> shows the distribution of events in the three groups according to the behavior of HDL-c. </p>
      <table-wrap id="tab04-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt04-en.jpg"/></table-wrap>
      <p>The group with low HDL-c in both assessments showed a significantly greater percentage of CV events than the other two groups. 13 CV events occurred in the normal group (41.9%), 16 (76.2%) in the low group, and 12 (41.4%) in the variable group (&#967;<sup>2 </sup>= 7, 419, p = 0024). </p>
      <p><xref ref-type="table" rid="tab05-body3">Table 5</xref> shows the distribution of types of events, showing that there was no difference among the groups as to the type of CV event. </p>
      <table-wrap id="tab05-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt05-en.jpg"/></table-wrap>
      <p>In a logistic regression model the occurrence of events was considered as a dependent variable; in turn, age, SBP, DBP, cholesterol, HDL-c and triglycerides values obtained in the first assessment were considered as independent variables. In this model, only age and HDL-c had a significant correlation with the occurrence of CV events. We observed that the older the patient, the greater the occurrence of cardiovascular events (odds ratio = 1.187, p = 0.0230). We also observed that the lower the HDL-c, the greater the occurrence of cardiovascular events (odds ratio = 0.9375, p = 0.0102) (<xref ref-type="table" rid="tab06-body3">table 6</xref>).</p>
      <table-wrap id="tab06-body3">
        <graphic xlink:href="1678-4170-abc-93-03-0231-00006-gt06-en.jpg"/></table-wrap>
      <p>The analysis of the distribution of deaths showed no statistically significant difference (&#967;<sup>2</sup> = 1.359, p = 0.507). </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>In addition to increased life expectancy at birth, chronic disability and institutionalization have also shown higher prevalence among the elderly, with a predominance in women<sup>1</sup>. As a result of the increased prevalence of chronic degenerative diseases and their sequelae, functional dependence is an additional challenge<sup>2</sup>. In 2005, the per capita expenditure of the hospitals of the Unified Health System (SUS) with men aged from 60 to 69 years was over four times higher than that spent with men aged from 30 to 39 years, but only half of the group had 80 years or over<sup>23</sup>. </p>
      <p>The magnitude of the demographic and epidemiological changes requires the urgent adoption of a health care policy for the elderly<sup>23</sup>. Health expectation is even more important than life expectancy, and this is a challenge raised by the World Health Organization: "How to prevent and postpone disease and disability, and to maintain the health, independence and mobility of an aging population?"<sup>1</sup>.</p>
      <p>CVD is the leading cause of death and disability among individuals aged 65 years or over, despite the gradual decline of CVD in the population since the 70's. Therefore, CVD preventive measures have acquired special importance<sup>1,24</sup>. CVD has a significant impact on life expectancy, and it contributes to a deterioration in quality of life, leading to loss of independence and institutionalization. </p>
      <p>Numerous studies have addressed the influence of RF in the genesis of atherosclerosis<sup>25-28</sup>. However, the literature presents controversial results regarding the predictive value of some risk factors for CVD in the elderly, especially after 75 years<sup>29,30</sup>. The emergence of studies on risk factors for atherosclerosis, with appropriate design for the elderly, has revealed new facts<sup>30</sup>, although the results still show some discrepancies among them. </p>
      <p>Several articles have considered aging as one of the most important independent RF for morbidity and mortality from CVD, and the vascular endothelium is a clear body target<sup>25,28,31</sup>. Luscher and Barton<sup>31</sup> studied the influence of age, hypertension and lipids on the vascular endothelium, and observed that all three conditions were associated with functional changes in the endothelium and could contribute to vascular proliferation, thrombosis, vasospasm and ischemia. Within the context of risk factors, this study was designed to establish the importance of HDL-c for the occurrence of CVD in the elderly. </p>
      <p>Initially, we compared the epidemiological variables of the three groups. An evaluation of the mean values for age, gender and follow-up time showed homogeneity among the three groups, with no statistically significant difference, and therefore no influence on the analysis of events. </p>
      <p>The anthropometric indices used were weight, height and body mass index (BMI), which was used due to its good correlation with direct measurement of body fat. In this study, there were no differences among the groups regarding the average anthropometric variables analyzed, which is in agreement with the study by Price, in which BMI was not positively associated with CV mortality in men and women<sup>32</sup>. </p>
      <p>Mean SBP and DBP values showed no statistical differences among the three groups in both assessments, and they did not interfere with the results. A recent analysis of the <italic>Framingham Heart Study</italic> showed that the accumulation of RF, including high blood pressure, contributes to lower survival and greater inability in the elderly<sup>33</sup>. The effects of BP on CV morbidity and mortality are well established<sup>34</sup>. In this study, BP assessed by logistic regression model showed no statistically significant association with cardiovascular events. </p>
      <p>The metabolic variables were determined in the initial phase of study, assessment 1, and reassessed after at least five years in assessment 2; these values were correlated with the events that occurred during the study. </p>
      <p>High levels of total cholesterol and LDL-c have been shown to be important risk factors for the incidence of CVD and total mortality in middle-aged individuals in several studies, including the Honolulu Heart Program (HHP)<sup>18</sup>. However, these findings in the elderly have been less consistent. In the HHP, the proportion of reduction in the rate of events was similar in young subjects and in the elderly over 70 years. In the results obtained in this study, there was no relationship among CVD, total cholesterol and LDL-c in the elderly. </p>
      <p>The analysis of cholesterol mean values in assessment 1 showed higher values in comparison to the values obtained in assessment 2 in all groups; therefore, lower values were obtained in older individuals. This observation is in agreement with the literature, which describes a reduction in the prevalence of abnormal lipid profile with age<sup>24</sup>. Furthermore, the use of specific medication for the treatment of dyslipidemia could have contributed to the change observed. Also, some epidemiological studies suggest that the relationship between CAD and the levels of cholesterol undergoes a decline with age, which may have originated the belief that there would be less benefit in the treatment of cholesterol in the elderly<sup>24,35,36</sup>. However, some studies show positive results in regard to the treatment, as occurred in the <italic>Heart Protection Study<sup>18</sup></italic>, in which there was a subgroup of patients aged over 70 years, most of them with less than 75 years, and there was a reduction in vascular risk in this group. </p>
      <p>After using a logistic regression model in which the occurrence of events was considered as a dependent variable, and age, SBP, DBP, TC, HDL-c and TG as independent variables in assessment 1, we observed that cholesterol was not significantly associated with the development of cardiovascular events. </p>
      <p>Mean triglyceride levels were significantly different in the two assessments. In this study, the highest triglyceride levels occurred in the group with the lowest HDL-c levels, both in assessment 1 and in assessment 2, in agreement with the close association among reverse cholesterol transport, HDL-c and triglycerides<sup>37,38</sup>. However, in a logistic regression model, the variable triglycerides showed no significant relationship with CVD. While univariate analysis of epidemiological studies have shown that hypertriglyceridemia is associated with an increase in CAD in men and women, multivariate analysis have shown conflicting results for the characterization of triglycerides as an independent risk factor for CAD, which seems to be a more important factor for new events in women than in men<sup>8</sup>. </p>
      <p>The logistic regression model showed that the older the patient the greater the occurrence of CV events (odds ratio = 1.187, p = 0.0230), which is in agreement with the literature which describes a direct relationship between CV mortality and age<sup>38</sup>. </p>
      <p>The behavior of HDL-c showed statistical expression for the occurrence of events (&#967;<sup>2</sup> = 7419, p = 0024). In the analysis of logistic regression model, this relationship was maintained, showing that the higher the HDL-c levels the lower the occurrence of CV events. </p>
      <p>HDL-c has been identified as a major and independent risk factor, with greater association with the development of CAD than total cholesterol and LDL-c<sup>39</sup>. Another aspect that has been demonstrated is the predictive value of low HDL-c as a risk factor for CAD, which is higher in women than in men<sup>38</sup>.</p>
      <p>The antiatherogenic effects of HDL-c have been tentatively explained through its anti-inflammatory, antioxidant, antiplatelet, anticoagulant and pro-fibrinolytic properties, which promote the maintenance of endothelial function. Therefore, low levels of HDL-C would supposedly contribute to an increase in CVD by the loss of antiatherogenic effects, due to lower reverse cholesterol transport, lower anti-inflammatory action and loss of antithrombotic properties. </p>
      <p>Low levels of HDL-c are frequently observed in CAD patients, and genetic syndromes that lead to high HDL-c are frequently associated with reductions in the incidence of CAD and greater longevity<sup>40</sup>. The interest on HDL-c has become stronger, as it is often found in association with high levels of atherogenic lipoproteins, including VLDL and small dense LDL-c, and also with the metabolic syndrome, including insulin resistance, glucose intolerance and high blood pressure<sup>40</sup>. The complexity of the metabolism of HDL-c still needs further studies. </p>
      <p>The high occurrence of events in the three groups could be related to a direct association between events and mortality with age and time of exposure to RF<sup>33</sup>, so much so that in the low HDL-c group, only 23.8% of the patients did not show any event. However, there was no predominance of any specific type of CV event associated with the behavior of HDL-c. </p>
      <p>It must be emphasized that this was a longitudinal study, with a prolonged follow-up &#151; eight years &#151; and that its main contribution was to demonstrate the significant correlation of persistently low HDL-c with the occurrence of CV events. </p>
      <p>This study has limitations arising from the relatively small number of patients and it is not advisable to generalize its results, despite its important findings. The outcomes assessed are not all considered major; however, they may quite reasonably characterize the presence of significant atherosclerotic disease and cardiovascular events in a prospectively studied sample of elderly patients. Moreover, these conditions have great impact on the quality of life, which was one of the main objectives in the evaluation of this age group. </p>
      <p>In conclusion, the occurrence of permanently low values of HDL-c in the elderly, during an eight-year follow up, was associated with higher levels of triglycerides in both assessments, but was not related to blood pressure, anthropometric indices and LDL-c. Aging and permanently low HDL-c levels were risk factors for cardiovascular events, whereas total cholesterol and blood pressure showed no significant relationship. Data from this study emphasize the need for a lipid profile assessment in the elderly, so as to identify patients with increased risk for CV disease. </p>
      <p>
        <bold>Acknowledgments </bold>
      </p>
      <p>The authors thank Simone Offrede, a biologist from Hospital Universit&#225;rio Pedro Ernesto, who was responsible for the collection of blood samples and for patients call control.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Doctoral submitted by Elizabete Viana de Freitas, from Hospital Universit&#225;rio Pedro Ernesto da Universidade do Rio de Janeiro.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
